CA2378409A1 - Control of crustacean infestation of aquatic animals - Google Patents
Control of crustacean infestation of aquatic animals Download PDFInfo
- Publication number
- CA2378409A1 CA2378409A1 CA002378409A CA2378409A CA2378409A1 CA 2378409 A1 CA2378409 A1 CA 2378409A1 CA 002378409 A CA002378409 A CA 002378409A CA 2378409 A CA2378409 A CA 2378409A CA 2378409 A1 CA2378409 A1 CA 2378409A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- juvenile hormone
- group
- species
- fish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000238424 Crustacea Species 0.000 title claims abstract description 48
- 206010061217 Infestation Diseases 0.000 title claims abstract description 28
- 241001465754 Metazoa Species 0.000 title claims description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 188
- 241000251468 Actinopterygii Species 0.000 claims abstract description 118
- 229930014550 juvenile hormone Natural products 0.000 claims abstract description 104
- 239000002949 juvenile hormone Substances 0.000 claims abstract description 104
- 150000003633 juvenile hormone derivatives Chemical class 0.000 claims abstract description 104
- 239000003814 drug Substances 0.000 claims abstract description 36
- 241000277263 Salmo Species 0.000 claims abstract description 17
- 241000277331 Salmonidae Species 0.000 claims abstract description 11
- 241001405819 Caligus elongatus Species 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 46
- -1 2,2-dimethylcyclopropyl Chemical group 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 230000003054 hormonal effect Effects 0.000 claims description 23
- 241000894007 species Species 0.000 claims description 22
- 239000004530 micro-emulsion Substances 0.000 claims description 21
- 241001247234 Lepeophtheirus salmonis Species 0.000 claims description 19
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 18
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 18
- FYQGBXGJFWXIPP-UHFFFAOYSA-N hydroprene Chemical compound CCOC(=O)C=C(C)C=CCC(C)CCCC(C)C FYQGBXGJFWXIPP-UHFFFAOYSA-N 0.000 claims description 18
- 229930000073 hydroprene Natural products 0.000 claims description 18
- 229930002897 methoprene Natural products 0.000 claims description 18
- 229950003442 methoprene Drugs 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 229920002101 Chitin Polymers 0.000 claims description 13
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 239000011593 sulfur Chemical group 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 241000277334 Oncorhynchus Species 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 241001266069 Livoneca Species 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 230000003071 parasitic effect Effects 0.000 claims description 8
- HJUFTIJOISQSKQ-UHFFFAOYSA-N fenoxycarb Chemical compound C1=CC(OCCNC(=O)OCC)=CC=C1OC1=CC=CC=C1 HJUFTIJOISQSKQ-UHFFFAOYSA-N 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 150000003505 terpenes Chemical class 0.000 claims description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- FZRBKIRIBLNOAM-UHFFFAOYSA-N (E,E)-2-propynyl 3,7,11-trimethyl-2,4-dodecadienoate Chemical compound CC(C)CCCC(C)CC=CC(C)=CC(=O)OCC#C FZRBKIRIBLNOAM-UHFFFAOYSA-N 0.000 claims description 5
- YHDXOFFTMOZZPE-UHFFFAOYSA-N 2-ethyl-3-[3-ethyl-5-(4-ethylphenoxy)pentyl]-2-methyloxirane Chemical compound O1C(CC)(C)C1CCC(CC)CCOC1=CC=C(CC)C=C1 YHDXOFFTMOZZPE-UHFFFAOYSA-N 0.000 claims description 5
- QAEVVTVIOGTPLI-UHFFFAOYSA-N 3-[(4-phenoxyphenyl)methoxy]pyridine Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1COC1=CC=CN=C1 QAEVVTVIOGTPLI-UHFFFAOYSA-N 0.000 claims description 5
- 241000277275 Oncorhynchus mykiss Species 0.000 claims description 5
- 229930001540 kinoprene Natural products 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 5
- 239000002728 pyrethroid Substances 0.000 claims description 5
- YGBMMMOLNODPBP-GWGZPXPZSA-N s-ethyl (2e,4e)-11-methoxy-3,7,11-trimethyldodeca-2,4-dienethioate Chemical compound CCSC(=O)\C=C(/C)\C=C\CC(C)CCCC(C)(C)OC YGBMMMOLNODPBP-GWGZPXPZSA-N 0.000 claims description 5
- OQJRUUUFRQCENE-UHFFFAOYSA-N 1-octylpiperidine Chemical compound CCCCCCCCN1CCCCC1 OQJRUUUFRQCENE-UHFFFAOYSA-N 0.000 claims description 4
- QKJJUQOUDLVMCG-UHFFFAOYSA-N 2-[2-(4-phenoxyphenoxy)ethoxy]pyridine Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1OCCOC1=CC=CC=N1 QKJJUQOUDLVMCG-UHFFFAOYSA-N 0.000 claims description 4
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 claims description 4
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 4
- NMLNNXGEQCSYGQ-UHFFFAOYSA-N 4-octylmorpholine Chemical compound CCCCCCCCN1CCOCC1 NMLNNXGEQCSYGQ-UHFFFAOYSA-N 0.000 claims description 4
- 241000009885 Anilocra physodes Species 0.000 claims description 4
- 241001611011 Caligus Species 0.000 claims description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 239000002270 dispersing agent Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- JDEPNKUINYBORA-UHFFFAOYSA-N 1,4-dioctylpiperazine Chemical compound CCCCCCCCN1CCN(CCCCCCCC)CC1 JDEPNKUINYBORA-UHFFFAOYSA-N 0.000 claims description 3
- TWOLMUQSOOZPPE-UHFFFAOYSA-N 2-(3,7-dimethyloctylsulfanyl)thiophene Chemical compound CC(C)CCCC(C)CCSC1=CC=CS1 TWOLMUQSOOZPPE-UHFFFAOYSA-N 0.000 claims description 3
- 241000009884 Anilocra Species 0.000 claims description 3
- 241000473391 Archosargus rhomboidalis Species 0.000 claims description 3
- 241000790794 Argulus Species 0.000 claims description 3
- 241000239250 Copepoda Species 0.000 claims description 3
- 241001149911 Isopoda Species 0.000 claims description 3
- 241001247233 Lepeophtheirus Species 0.000 claims description 3
- 241000277326 Oncorhynchus gorbuscha Species 0.000 claims description 3
- 241000277329 Oncorhynchus keta Species 0.000 claims description 3
- 241000277338 Oncorhynchus kisutch Species 0.000 claims description 3
- 241001280377 Oncorhynchus tshawytscha Species 0.000 claims description 3
- 241000277289 Salmo salar Species 0.000 claims description 3
- 241000277295 Salvelinus Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000269858 Anarhichas lupus Species 0.000 claims description 2
- 241000040006 Elthusa vulgaris Species 0.000 claims description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 claims description 2
- 241000013856 Olencira Species 0.000 claims description 2
- 241000013857 Olencira praegustator Species 0.000 claims description 2
- 241000269908 Platichthys flesus Species 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 229960005349 sulfur Drugs 0.000 claims 7
- 235000001508 sulfur Nutrition 0.000 claims 7
- 229960005419 nitrogen Drugs 0.000 claims 6
- JOZSNVOTRXIUNJ-UHFFFAOYSA-N 3-[2-(4-phenoxyphenoxy)ethoxy]pyridine Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1OCCOC1=CC=CN=C1 JOZSNVOTRXIUNJ-UHFFFAOYSA-N 0.000 claims 2
- 241000239265 Branchiura <Crustacea> Species 0.000 claims 2
- 239000005898 Fenoxycarb Substances 0.000 claims 2
- 241000277288 Salmo trutta Species 0.000 claims 2
- 229910001369 Brass Inorganic materials 0.000 claims 1
- 241000276438 Gadus morhua Species 0.000 claims 1
- 241000269980 Pleuronectidae Species 0.000 claims 1
- 239000010951 brass Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 229960003903 oxygen Drugs 0.000 claims 1
- 235000019688 fish Nutrition 0.000 abstract description 118
- 238000011282 treatment Methods 0.000 abstract description 32
- 229940079593 drug Drugs 0.000 abstract description 21
- 208000028454 lice infestation Diseases 0.000 abstract description 5
- 241001674048 Phthiraptera Species 0.000 description 57
- 241000133262 Nauplius Species 0.000 description 37
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 36
- 230000000694 effects Effects 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- 229930191400 juvenile hormones Natural products 0.000 description 29
- 238000011161 development Methods 0.000 description 24
- 230000018109 developmental process Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 241000238631 Hexapoda Species 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- 239000013535 sea water Substances 0.000 description 16
- 230000001276 controlling effect Effects 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 244000045947 parasite Species 0.000 description 11
- 229940022682 acetone Drugs 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 8
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 8
- 244000078703 ectoparasite Species 0.000 description 8
- 229960002418 ivermectin Drugs 0.000 description 8
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 241000972773 Aulopiformes Species 0.000 description 6
- OEBRKCOSUFCWJD-UHFFFAOYSA-N dichlorvos Chemical compound COP(=O)(OC)OC=C(Cl)Cl OEBRKCOSUFCWJD-UHFFFAOYSA-N 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 230000000366 juvenile effect Effects 0.000 description 6
- 235000019515 salmon Nutrition 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000005893 Diflubenzuron Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 5
- 239000005938 Teflubenzuron Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- QQQYTWIFVNKMRW-UHFFFAOYSA-N diflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC=C(Cl)C=C1 QQQYTWIFVNKMRW-UHFFFAOYSA-N 0.000 description 5
- 229940019503 diflubenzuron Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000001418 larval effect Effects 0.000 description 5
- 230000029052 metamorphosis Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- CJDWRQLODFKPEL-UHFFFAOYSA-N teflubenzuron Chemical compound FC1=CC=CC(F)=C1C(=O)NC(=O)NC1=CC(Cl)=C(F)C(Cl)=C1F CJDWRQLODFKPEL-UHFFFAOYSA-N 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229950001327 dichlorvos Drugs 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000013505 freshwater Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WEGQSMDVKYYUPG-UHFFFAOYSA-N 3-(3,7-dimethyloctoxy)pyridine Chemical compound CC(C)CCCC(C)CCOC1=CC=CN=C1 WEGQSMDVKYYUPG-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014143 Ectoparasitic Infestations Diseases 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- WPPOGHDFAVQKLN-UHFFFAOYSA-N N-Octyl-2-pyrrolidone Chemical compound CCCCCCCCN1CCCC1=O WPPOGHDFAVQKLN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000002141 anti-parasite Effects 0.000 description 3
- 238000003287 bathing Methods 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960001952 metrifonate Drugs 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 208000029380 parasitic ectoparasitic infectious disease Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- NFACJZMKEDPNKN-UHFFFAOYSA-N trichlorfon Chemical compound COP(=O)(OC)C(O)C(Cl)(Cl)Cl NFACJZMKEDPNKN-UHFFFAOYSA-N 0.000 description 3
- LVQFGKMCIGFCST-UHFFFAOYSA-N 2-methyl-5-octoxypyridine Chemical compound CCCCCCCCOC1=CC=C(C)N=C1 LVQFGKMCIGFCST-UHFFFAOYSA-N 0.000 description 2
- MKXPLUCMXAMDBY-UHFFFAOYSA-N 3,7-dimethyloctoxybenzene Chemical compound CC(C)CCCC(C)CCOC1=CC=CC=C1 MKXPLUCMXAMDBY-UHFFFAOYSA-N 0.000 description 2
- MSHKRQZNUARPFF-UHFFFAOYSA-N 3-(4,8-dimethylnonyl)pyridine Chemical compound CC(C)CCCC(C)CCCC1=CC=CN=C1 MSHKRQZNUARPFF-UHFFFAOYSA-N 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 2
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
- 239000005892 Deltamethrin Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000269951 Labridae Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000382353 Pupa Species 0.000 description 2
- 241000316146 Salmo trutta trutta Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 229940125900 compound 59 Drugs 0.000 description 2
- 229960002483 decamethrin Drugs 0.000 description 2
- OWZREIFADZCYQD-NSHGMRRFSA-N deltamethrin Chemical compound CC1(C)[C@@H](C=C(Br)Br)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 OWZREIFADZCYQD-NSHGMRRFSA-N 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 150000002903 organophosphorus compounds Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000009372 pisciculture Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004546 suspension concentrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- HZDZRGKULMGCJE-NCZFFCEISA-N (2e,6e)-1-methoxy-3,7,11-trimethyldodeca-2,6,10-triene Chemical compound COC\C=C(/C)CC\C=C(/C)CCC=C(C)C HZDZRGKULMGCJE-NCZFFCEISA-N 0.000 description 1
- BZJTUOGZUKFLQT-UHFFFAOYSA-N 1,3,5,7-tetramethylcyclooctane Chemical group CC1CC(C)CC(C)CC(C)C1 BZJTUOGZUKFLQT-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VLZLAARBPXSSPH-UHFFFAOYSA-N 1,4-dioctylpiperidine Chemical compound CCCCCCCCC1CCN(CCCCCCCC)CC1 VLZLAARBPXSSPH-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- NJPQAIBZIHNJDO-UHFFFAOYSA-N 1-dodecylpyrrolidin-2-one Chemical compound CCCCCCCCCCCCN1CCCC1=O NJPQAIBZIHNJDO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FZNJWZDBSDVBAE-UHFFFAOYSA-N 2-(3,7-dimethyloctylsulfanyl)pyridine Chemical compound CC(C)CCCC(C)CCSC1=CC=CC=N1 FZNJWZDBSDVBAE-UHFFFAOYSA-N 0.000 description 1
- HMYUFOBJJSHXFK-UHFFFAOYSA-N 2-methyl-5-nonoxypyridine Chemical compound CCCCCCCCCOC1=CC=C(C)N=C1 HMYUFOBJJSHXFK-UHFFFAOYSA-N 0.000 description 1
- IMZXGVAUGRDJMQ-UHFFFAOYSA-N 3-(3,7-dimethyloctylsulfanyl)pyridine Chemical compound CC(C)CCCC(C)CCSC1=CC=CN=C1 IMZXGVAUGRDJMQ-UHFFFAOYSA-N 0.000 description 1
- FWUMGMDRJBFSOD-UHFFFAOYSA-N 4,8-dimethyl-1-pyridin-3-ylnonan-1-ol Chemical compound CC(C)CCCC(C)CCC(O)C1=CC=CN=C1 FWUMGMDRJBFSOD-UHFFFAOYSA-N 0.000 description 1
- DCNHHEKYZFLGIF-UHFFFAOYSA-N 4,8-dimethyl-1-pyridin-3-ylnonan-1-one Chemical compound CC(C)CCCC(C)CCC(=O)C1=CC=CN=C1 DCNHHEKYZFLGIF-UHFFFAOYSA-N 0.000 description 1
- IPYRAUOTBYUFIK-UHFFFAOYSA-N 5-(3,7-dimethyloctoxy)-1,3-benzodioxole Chemical compound CC(C)CCCC(C)CCOC1=CC=C2OCOC2=C1 IPYRAUOTBYUFIK-UHFFFAOYSA-N 0.000 description 1
- HJKHVUURJUFFRF-UHFFFAOYSA-N 5-(3,7-dimethyloctoxy)-2-methylpyridine Chemical compound CC(C)CCCC(C)CCOC1=CC=C(C)N=C1 HJKHVUURJUFFRF-UHFFFAOYSA-N 0.000 description 1
- XZWBLRMBDRWQKM-UHFFFAOYSA-N 5-(3,7-dimethyloctoxy)-2-methylpyrimidine Chemical compound CC(C)CCCC(C)CCOC1=CN=C(C)N=C1 XZWBLRMBDRWQKM-UHFFFAOYSA-N 0.000 description 1
- JKJBGRJNTIJAJQ-UHFFFAOYSA-N 5-[5-(2,2-dimethylcyclopropyl)-3-methylpentoxy]-2-methylpyridine Chemical compound C1C(C)(C)C1CCC(C)CCOC1=CC=C(C)N=C1 JKJBGRJNTIJAJQ-UHFFFAOYSA-N 0.000 description 1
- RZRRIGCRQHCDRS-UHFFFAOYSA-N 5-dodecoxy-2-methylpyridine Chemical compound CCCCCCCCCCCCOC1=CC=C(C)N=C1 RZRRIGCRQHCDRS-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000252087 Anguilla japonica Species 0.000 description 1
- 241001124076 Aphididae Species 0.000 description 1
- 241000239201 Argulidae Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 241001195214 Brachiella Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000276694 Carangidae Species 0.000 description 1
- 241000369098 Chondracanthidae Species 0.000 description 1
- 241000276616 Cichlidae Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000005946 Cypermethrin Substances 0.000 description 1
- 241000252210 Cyprinidae Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000618288 Ergasilidae Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 241001205608 Hatschekia Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 241000442132 Lactarius lactarius Species 0.000 description 1
- 241000696958 Lernaea Species 0.000 description 1
- 241001206069 Lernaeocera Species 0.000 description 1
- 241001593519 Liza affinis Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000101788 Pennella <fungus> Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000269907 Pleuronectes platessa Species 0.000 description 1
- 239000005927 Pyriproxyfen Substances 0.000 description 1
- ISRUGXGCCGIOQO-UHFFFAOYSA-N Rhoden Chemical compound CNC(=O)OC1=CC=CC=C1OC(C)C ISRUGXGCCGIOQO-UHFFFAOYSA-N 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 241000258242 Siphonaptera Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000766285 Sphyriidae Species 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 241000886165 Symphodus Species 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- VNKBTWQZTQIWDV-UHFFFAOYSA-N azamethiphos Chemical compound C1=C(Cl)C=C2OC(=O)N(CSP(=O)(OC)OC)C2=N1 VNKBTWQZTQIWDV-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000002251 corpora allata Anatomy 0.000 description 1
- 229960005424 cypermethrin Drugs 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001083 documented effect Effects 0.000 description 1
- YRIUSKIDOIARQF-UHFFFAOYSA-N dodecyl benzenesulfonate Chemical class CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 YRIUSKIDOIARQF-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002058 ecdysones Chemical class 0.000 description 1
- 239000004495 emulsifiable concentrate Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MXYHUYGRMOJHIQ-UHFFFAOYSA-N ethyl 9-(2,2-dichloro-3,3-dimethylcyclopropyl)-7-methylnona-2,4-dienoate Chemical compound CCOC(=O)C=CC=CCC(C)CCC1C(C)(C)C1(Cl)Cl MXYHUYGRMOJHIQ-UHFFFAOYSA-N 0.000 description 1
- NAWFMEHNGFMVSM-UHFFFAOYSA-N ethyl 9-(2,2-dimethylcyclopropyl)-7-methylnona-2,4-dienoate Chemical compound CCOC(=O)C=CC=CCC(C)CCC1CC1(C)C NAWFMEHNGFMVSM-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- DIRFUJHNVNOBMY-UHFFFAOYSA-N fenobucarb Chemical compound CCC(C)C1=CC=CC=C1OC(=O)NC DIRFUJHNVNOBMY-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000010824 fish disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000201 insect hormone Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229930000024 juvenile hormones I Natural products 0.000 description 1
- 229930002340 juvenile hormones II Natural products 0.000 description 1
- 229930000772 juvenile hormones III Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000974 larvacidal effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- NOPCRSLRJIYLJH-UHFFFAOYSA-N methyl 9-(2,2-dichloro-3,3-dimethylcyclopropyl)-7-methylnona-2,4-dienoate Chemical compound COC(=O)C=CC=CCC(C)CCC1C(C)(C)C1(Cl)Cl NOPCRSLRJIYLJH-UHFFFAOYSA-N 0.000 description 1
- FNTGCXPLWNAYQT-UHFFFAOYSA-N methyl 9-(2,2-dimethylcyclopropyl)-7-methylnona-2,4-dienoate Chemical compound COC(=O)C=CC=CCC(C)CCC1CC1(C)C FNTGCXPLWNAYQT-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 239000004466 pelleted feed Substances 0.000 description 1
- 229960000490 permethrin Drugs 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- NSVDOFGFOYFGEV-UHFFFAOYSA-N propan-2-yl 9-(2,2-dichloro-3,3-dimethylcyclopropyl)-7-methylnona-2,4-dienoate Chemical compound CC(C)OC(=O)C=CC=CCC(C)CCC1C(C)(C)C1(Cl)Cl NSVDOFGFOYFGEV-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940015367 pyrethrum Drugs 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229940108410 resmethrin Drugs 0.000 description 1
- VEMKTZHHVJILDY-FIWHBWSRSA-N resmethrin Chemical compound CC1(C)[C@H](C=C(C)C)C1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-FIWHBWSRSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- FODHIQQNHOPUKH-UHFFFAOYSA-N tetrapropylene-benzenesulfonic acid Chemical compound CC1CC11C2=C3S(=O)(=O)OC(C)CC3=C3C(C)CC3=C2C1C FODHIQQNHOPUKH-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N49/00—Biocides, pest repellants or attractants, or plant growth regulators, containing compounds containing the group, wherein m+n>=1, both X together may also mean —Y— or a direct carbon-to-carbon bond, and the carbon atoms marked with an asterisk are not part of any ring system other than that which may be formed by the atoms X, the carbon atoms in square brackets being part of any acyclic or cyclic structure, or the group, wherein A means a carbon atom or Y, n>=0, and not more than one of these carbon atoms being a member of the same ring system, e.g. juvenile insect hormones or mimics thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P15/00—Biocides for specific purposes not provided for in groups A01P1/00 - A01P13/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Agronomy & Crop Science (AREA)
- Insects & Arthropods (AREA)
- Dentistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Farming Of Fish And Shellfish (AREA)
- Fodder In General (AREA)
Abstract
Use of juvenile hormone analogue compounds (juvenoids, juvenile hormone mimics) for the control of crustacean infestation in fish, such as sea lice infestation, in particular infestations withlepeophtheirus salmonis and caligus elongatus in wild and farmed fish of the family salmonidae including Atlantic salmon and trout. The compounds are preferably administered via the feed or as bath treatment medication.
Description
CONTROL OF CRUSTACEAN INFESTATION OF AQUATIC ANIMALS
FIELD OF INVENTION
The present invention relates in its broadest aspect to the production of aquatic animals such as fish. In particular there is provided novel and improved means of controlling para-sitic crustacean infestations of fish, including farmed fish, using juvenile hormone ana-logue compounds.
TECHNICAL BACKGROUND AND PRIOR ART
Ectoparasitic infestations constitute considerable problems in the fish farming industry as well as in wild fish. However, the problems are particularly serious in farmed fish in both fresh water and sea water environments. Damages due to ectoparasitic infestations of fish result in considerable losses and increased workloads for fish farmers. Among ectopara-sites in fish and other aquatic animals, parasitic species of crustacean ectoparasites, also generally referred to as sea lice, are particularly harmful. Thus, infestation with sea lice in-cluding Lepeophtheirus salmonis and Caligus elongatus is considered to be one of the most important disease problems in farming of salmonids, especially in Atlantic salmon (Salmo salary and rainbow trout (Oncorhynchus mykiss). In addition to the costs that are associated with treatment, lower classification ratings of slaughtered fish and reduced growth rate due to reduced feed intake contribute to the economic losses caused by sea lice.
The life cycle of Lepeophtheirus salmonis is direct, meaning that no intermediate host is required for the development of the adult lice. The two nauplius stages of this species are pelagic. The infective stage, the copepodites, attach to fish, normally on their ventral surfaces and on the fins. It moults to the first chalimus stage, which is attached to its host by a frontal filament projecting from the leading edge of the parasite's carapace. All four chalimus stages are attached to the host by this filament. At the moult to the first pre-adult stage, the frontal filament is normally lost, and the parasite may move around on the skin of the host. Adult males may mate with pre-adult females, which may therefore already be pregnant when they moult to adults. The eggs are stored in egg sacs hanging from the genital segment of the body. The completion of the life cycle normally takes about six weeks at a water temperature between 9 and 12°C. The life cycle of Caligus elongatus is similar to that of Lepeophtheirus salmonis.
In addition to the damages caused in farmed fish, recent research has shown that sea lice could be the most important single cause leading to weakening of several wild salmon stocks. The emigration of salmon smolt from river systems is often coincidental with rising sea water temperatures in the fjord and coastal areas, which leads to a massive attack of copepodites (sea lice larvae) on the smolt. An attack of 40 or more sea lice on salmon smolt is fatal to fish weighing less than 25 grams, and in several regions premature return of post-smolt sea trout has been observed. The decline in the stock of salmonids that have been documented in several salmon rivers over the past few years, could be related to the fact that the amount of sea lice in connection with fish farming has increased.
Up till now, the most common treatment of fish ectoparasites involves bathing or immers-ing the fish in a treatment solution comprising an antiparasitically active compound. This includes both skin and gill parasites. Bathing in formalin is a widespread treatment against many ectoparasites, especially in fresh water, while bathing in a solution of an organo-phosphate such as e.g. metrifonate, dichlorvos or azamethiphos, a pyrethroid compound such as pyrethrum, cypermethrin or deltamethrin (WO 92/16106), or hydrogen peroxide are the most common bath treatments against e.g. sea lice. These compounds act directly on the ectoparasites via the water and a possible absorption of the active substance into the fish itself is unimportant for the effect of the active substances on the parasite.
Substances that are effective against parasitic infestations via oral administration have also been tested in fish. Substances such as the chitin synthesis inhibitors diflubenzuron and teflubenzuron, are examples of substances, which, if administered orally, can be ef-fective against parasitic diseases in fish. In addition to the substances mentioned above, wrasse (Labridae) has been used extensively to keep sea lice infestations under control.
Organophosphates and hydrogen peroxide are only effective against the pre-adult and adult stages of sea lice (the last 3 stages of the total of 8 stages which exist on the skin of salmonids), while pyrethroids and ivermectin also have a more or less well-defined effect against the other 5 stages. None of these substances protect against new infestations af-ter the treatment has been completed.
FIELD OF INVENTION
The present invention relates in its broadest aspect to the production of aquatic animals such as fish. In particular there is provided novel and improved means of controlling para-sitic crustacean infestations of fish, including farmed fish, using juvenile hormone ana-logue compounds.
TECHNICAL BACKGROUND AND PRIOR ART
Ectoparasitic infestations constitute considerable problems in the fish farming industry as well as in wild fish. However, the problems are particularly serious in farmed fish in both fresh water and sea water environments. Damages due to ectoparasitic infestations of fish result in considerable losses and increased workloads for fish farmers. Among ectopara-sites in fish and other aquatic animals, parasitic species of crustacean ectoparasites, also generally referred to as sea lice, are particularly harmful. Thus, infestation with sea lice in-cluding Lepeophtheirus salmonis and Caligus elongatus is considered to be one of the most important disease problems in farming of salmonids, especially in Atlantic salmon (Salmo salary and rainbow trout (Oncorhynchus mykiss). In addition to the costs that are associated with treatment, lower classification ratings of slaughtered fish and reduced growth rate due to reduced feed intake contribute to the economic losses caused by sea lice.
The life cycle of Lepeophtheirus salmonis is direct, meaning that no intermediate host is required for the development of the adult lice. The two nauplius stages of this species are pelagic. The infective stage, the copepodites, attach to fish, normally on their ventral surfaces and on the fins. It moults to the first chalimus stage, which is attached to its host by a frontal filament projecting from the leading edge of the parasite's carapace. All four chalimus stages are attached to the host by this filament. At the moult to the first pre-adult stage, the frontal filament is normally lost, and the parasite may move around on the skin of the host. Adult males may mate with pre-adult females, which may therefore already be pregnant when they moult to adults. The eggs are stored in egg sacs hanging from the genital segment of the body. The completion of the life cycle normally takes about six weeks at a water temperature between 9 and 12°C. The life cycle of Caligus elongatus is similar to that of Lepeophtheirus salmonis.
In addition to the damages caused in farmed fish, recent research has shown that sea lice could be the most important single cause leading to weakening of several wild salmon stocks. The emigration of salmon smolt from river systems is often coincidental with rising sea water temperatures in the fjord and coastal areas, which leads to a massive attack of copepodites (sea lice larvae) on the smolt. An attack of 40 or more sea lice on salmon smolt is fatal to fish weighing less than 25 grams, and in several regions premature return of post-smolt sea trout has been observed. The decline in the stock of salmonids that have been documented in several salmon rivers over the past few years, could be related to the fact that the amount of sea lice in connection with fish farming has increased.
Up till now, the most common treatment of fish ectoparasites involves bathing or immers-ing the fish in a treatment solution comprising an antiparasitically active compound. This includes both skin and gill parasites. Bathing in formalin is a widespread treatment against many ectoparasites, especially in fresh water, while bathing in a solution of an organo-phosphate such as e.g. metrifonate, dichlorvos or azamethiphos, a pyrethroid compound such as pyrethrum, cypermethrin or deltamethrin (WO 92/16106), or hydrogen peroxide are the most common bath treatments against e.g. sea lice. These compounds act directly on the ectoparasites via the water and a possible absorption of the active substance into the fish itself is unimportant for the effect of the active substances on the parasite.
Substances that are effective against parasitic infestations via oral administration have also been tested in fish. Substances such as the chitin synthesis inhibitors diflubenzuron and teflubenzuron, are examples of substances, which, if administered orally, can be ef-fective against parasitic diseases in fish. In addition to the substances mentioned above, wrasse (Labridae) has been used extensively to keep sea lice infestations under control.
Organophosphates and hydrogen peroxide are only effective against the pre-adult and adult stages of sea lice (the last 3 stages of the total of 8 stages which exist on the skin of salmonids), while pyrethroids and ivermectin also have a more or less well-defined effect against the other 5 stages. None of these substances protect against new infestations af-ter the treatment has been completed.
Hydrogen peroxide is corrosive, and must therefore be handled with great care.
Transport of hydrogen peroxide requires certain precautionary measures, as it is defined as hazard-ous goods in great quantities. The organophosphates are toxic to humans and must therefore be treated with caution. The organophosphates can be absorbed through the skin and lead to poisoning. The therapeutic margin for organophosphates and hydrogen peroxide is small. Fish mortality has been reported on several occasions, due to over-dosing of such drugs.
Pyrethroids have, in addition to their effect against pre-adult and adult lice, also an effect against the attached stages. They are not acutely toxic to the user, but is a drug group that is toxic to fish, especially small fish. Overdosing and increased mortality of the target fish is thus possible.
In addition to bath treatments, oral treatments for parasite control in fish have been devel-oped. Two chitin synthesis inhibitors, diflubenzuron and teflubenzuron, have been docu-mented for use against sea lice in salmon.
Diflubenzuron and teflubenzuron act by inhibiting the synthesis of chitin which is an im portant component of the cuticle of insects and crustaceans. At each moulting or ectdysis, a new synthesis of chitin is required for development. If this synthesis is inhibited, the de-velopment of the insect or crustacean will be halted, and the animal under development will die. In principle, chitin synthesis inhibitors will be effective against all organisms con-taining chitin. Fish and mammals do not contain chitin and will therefore not be affected by substances within this drug group. This is reflected in very low toxicity for fish and mam-mals, including humans. Diflubenzuron and teflubenzuron are administered to the fish via the feed, absorbed and distributed to skin and mucus, where the concentration will be high enough to inhibit the development of the parasite. The disadvantages of diflubenzu-ron and teflubenzuron include that these substances have no effect against adult stages of the ectoparasites which do not actively synthesise chitin. Neither do they have any ef-fect beyond the period of treatment, as attacks by new parasites may occur within days of completing the treatment. This is due to the fact that the substances are eliminated rela-tively fast so that the concentration hereof rapidly ends up below therapeutically active levels in skin and mucus. The treatment must therefore be repeated if there is a continu-ous risk of parasite infection from the surroundings which, under normal circumstances, is often the case.
Ivermectin impairs the transfer of neural impulses in insects and crustaceans.
This leads to paralysis and death. Mammals and fish are also affected by ivermectin.
However, the same transfer mechanisms that are affected in insects, are only found in the brain of fish and mammals. Mammals have an advanced blood-brain barrier which prevents toxic ef-fect from lower concentrations. The blood-brain barrier in fish is less developed and this causes a substantial transition to the brain of ivermectin in treated fish, and toxic symp-toms are found at relatively low concentrations. Ivermectin, however, is effective for treatment of ectoparasites in fish provided that precautions with the dosing are taken.
Toxic effects and mortality may arise if the fish are overdosed. Ivermectin is often dosed 1 or 2 times a week to control sea lice infestation in salmonids. This means that the sub-stance must be added on a continuous basis to maintain therapeutic effect and keep the fish reasonably free of lice. Ivermectin is eliminated at a slow rate which means that the effect of the treatment is maintained for 2 to 3 weeks after the treatment has been com-pleted. This also means, however, that the treatment involves a long withdrawal period before the fish can be slaughtered and consumed. Up till now, ivermectin has not been approved for use in fish in any country.
As it appears from the above summary of the state-of-the-art, there is an industrial need for improved means of controlling parasitic infestations in fish, which are antiparasitically effective and non-toxic to the fish and which are non-toxic to the end-user and environ-mentally friendly.
The metamorphosis of arthropods (insect and crustacean species) is controlled by several hormones. In insects, such hormones include moulting hormones (MN), also referred to as ecdysones, and juvenile hormones (JH) that are terpenoid compounds.
Together with the moulting hormones circulating in the bloodstream of the insects, the juvenile hor-mones that are released from the corpora allata in the insect's head play vital roles in growth, development and reproduction of insects. If insects are treated with an excess of the juvenile hormone at an early stage in their development, they remain at a juvenile stage or develop into a sterile adult insect.
Whereas natural JHs have not been used commercially as insect controlling compounds, several JH analogues (JHAs), also referred to herein as juvenile hormone-like com-pounds, juvenoids or JH mimics, are used as insect controlling compounds.
Examples of such compounds include epofenonane, triprene, methoprene, hydroprene, kinoprene, 5 phenoxycarb and those compounds disclosed in US 4,061,757. Currently, typical uses of JH analogues include control of mosquitoes, mites, ants, aphids, cockroaches and fleas.
It has now been discovered that compounds having juvenile hormone activity in insects are highly active in the control of crustacean infestations of aquatic animals.
SUMMARY OF THE INVENTION
Accordingly, the present invention pertains in a first aspect to the use of a compound having juvenile hormone activity, in the manufacturing of a medicament for controlling crustacean infestation of aquatic animals including fish such as wild and farmed fish of the Salmonidae family.
In a further aspect, there are provided novel juvenile hormone analogue compounds se-lected from the group consisting of (i) a compound of the general formula I
R~ X ~ ~ R2 Y Z
where R' is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted isoprenoid or alkoxy substituted alkyl, RZ is hydrogen or alkyl, X is oxygen, sulfur, methyl-ene, carbinol or carbonyl, Y is nitrogen or methine and Z is nitrogen, methine or nitrogen oxide;
Transport of hydrogen peroxide requires certain precautionary measures, as it is defined as hazard-ous goods in great quantities. The organophosphates are toxic to humans and must therefore be treated with caution. The organophosphates can be absorbed through the skin and lead to poisoning. The therapeutic margin for organophosphates and hydrogen peroxide is small. Fish mortality has been reported on several occasions, due to over-dosing of such drugs.
Pyrethroids have, in addition to their effect against pre-adult and adult lice, also an effect against the attached stages. They are not acutely toxic to the user, but is a drug group that is toxic to fish, especially small fish. Overdosing and increased mortality of the target fish is thus possible.
In addition to bath treatments, oral treatments for parasite control in fish have been devel-oped. Two chitin synthesis inhibitors, diflubenzuron and teflubenzuron, have been docu-mented for use against sea lice in salmon.
Diflubenzuron and teflubenzuron act by inhibiting the synthesis of chitin which is an im portant component of the cuticle of insects and crustaceans. At each moulting or ectdysis, a new synthesis of chitin is required for development. If this synthesis is inhibited, the de-velopment of the insect or crustacean will be halted, and the animal under development will die. In principle, chitin synthesis inhibitors will be effective against all organisms con-taining chitin. Fish and mammals do not contain chitin and will therefore not be affected by substances within this drug group. This is reflected in very low toxicity for fish and mam-mals, including humans. Diflubenzuron and teflubenzuron are administered to the fish via the feed, absorbed and distributed to skin and mucus, where the concentration will be high enough to inhibit the development of the parasite. The disadvantages of diflubenzu-ron and teflubenzuron include that these substances have no effect against adult stages of the ectoparasites which do not actively synthesise chitin. Neither do they have any ef-fect beyond the period of treatment, as attacks by new parasites may occur within days of completing the treatment. This is due to the fact that the substances are eliminated rela-tively fast so that the concentration hereof rapidly ends up below therapeutically active levels in skin and mucus. The treatment must therefore be repeated if there is a continu-ous risk of parasite infection from the surroundings which, under normal circumstances, is often the case.
Ivermectin impairs the transfer of neural impulses in insects and crustaceans.
This leads to paralysis and death. Mammals and fish are also affected by ivermectin.
However, the same transfer mechanisms that are affected in insects, are only found in the brain of fish and mammals. Mammals have an advanced blood-brain barrier which prevents toxic ef-fect from lower concentrations. The blood-brain barrier in fish is less developed and this causes a substantial transition to the brain of ivermectin in treated fish, and toxic symp-toms are found at relatively low concentrations. Ivermectin, however, is effective for treatment of ectoparasites in fish provided that precautions with the dosing are taken.
Toxic effects and mortality may arise if the fish are overdosed. Ivermectin is often dosed 1 or 2 times a week to control sea lice infestation in salmonids. This means that the sub-stance must be added on a continuous basis to maintain therapeutic effect and keep the fish reasonably free of lice. Ivermectin is eliminated at a slow rate which means that the effect of the treatment is maintained for 2 to 3 weeks after the treatment has been com-pleted. This also means, however, that the treatment involves a long withdrawal period before the fish can be slaughtered and consumed. Up till now, ivermectin has not been approved for use in fish in any country.
As it appears from the above summary of the state-of-the-art, there is an industrial need for improved means of controlling parasitic infestations in fish, which are antiparasitically effective and non-toxic to the fish and which are non-toxic to the end-user and environ-mentally friendly.
The metamorphosis of arthropods (insect and crustacean species) is controlled by several hormones. In insects, such hormones include moulting hormones (MN), also referred to as ecdysones, and juvenile hormones (JH) that are terpenoid compounds.
Together with the moulting hormones circulating in the bloodstream of the insects, the juvenile hor-mones that are released from the corpora allata in the insect's head play vital roles in growth, development and reproduction of insects. If insects are treated with an excess of the juvenile hormone at an early stage in their development, they remain at a juvenile stage or develop into a sterile adult insect.
Whereas natural JHs have not been used commercially as insect controlling compounds, several JH analogues (JHAs), also referred to herein as juvenile hormone-like com-pounds, juvenoids or JH mimics, are used as insect controlling compounds.
Examples of such compounds include epofenonane, triprene, methoprene, hydroprene, kinoprene, 5 phenoxycarb and those compounds disclosed in US 4,061,757. Currently, typical uses of JH analogues include control of mosquitoes, mites, ants, aphids, cockroaches and fleas.
It has now been discovered that compounds having juvenile hormone activity in insects are highly active in the control of crustacean infestations of aquatic animals.
SUMMARY OF THE INVENTION
Accordingly, the present invention pertains in a first aspect to the use of a compound having juvenile hormone activity, in the manufacturing of a medicament for controlling crustacean infestation of aquatic animals including fish such as wild and farmed fish of the Salmonidae family.
In a further aspect, there are provided novel juvenile hormone analogue compounds se-lected from the group consisting of (i) a compound of the general formula I
R~ X ~ ~ R2 Y Z
where R' is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted isoprenoid or alkoxy substituted alkyl, RZ is hydrogen or alkyl, X is oxygen, sulfur, methyl-ene, carbinol or carbonyl, Y is nitrogen or methine and Z is nitrogen, methine or nitrogen oxide;
(ii) a compound of general formula II
R' where R' is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, RZ is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
\ \ ~R2 R' where R' is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and RZ is methyl, ethyl or isopropyl, (iv) a compound of the general formula IV
X Ar where X is oxygen or sulfur and Ar is a heteroaromatic group, and (v) a compound selected from the group consisting of 55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperidine;
F-1:3-[2'-(4"-Phenoxyphenoxy)ethoxyjpyridine;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine; and F-5: 3-(4'-Phenoxybenzyloxy)pyridine.
for use as a medicament for treating or preventing crustacean infestations in an aquatic animal.
In a still further aspect the invention provides a method of controlling crustacean infesta-tion of an aquatic animal, the method comprising administering to said animal or to the aquatic environment of the animal an effective amount of a juvenile hormone analogue compound including any of the above novel compounds.
There is also provided a pharmaceutical composition for controlling crustacean infestation of an aquatic animal, comprising a juvenile hormone analogue compound and at least one pharmaceutically acceptable carrier, and an aquatic animal feed composition comprising a juvenile hormone analogue compound.
DETAILED DISCLOSURE OF THE INVENTION
A major objective of the present invention is to provide improved means for controlling crustacean ectoparasitic infestations in aquatic animals such as fish. The invention is based on the finding that a range of compounds having juvenile hormone activity gener-ally referred to as juvenile hormone analogues (JHAs), which are known to have insect controlling activities including insecticidal activity, have a strong inhibiting effect on the metamorphosis of parasitic crustacean species resulting in a high mortality of these para-sites not only in vitro but also in vivo, i.e. when the parasites are attached to the host ani-mal, rendering such compounds potentially useful in the control of such ectoparasitic in-festations in live fish.
R' where R' is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, RZ is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
\ \ ~R2 R' where R' is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and RZ is methyl, ethyl or isopropyl, (iv) a compound of the general formula IV
X Ar where X is oxygen or sulfur and Ar is a heteroaromatic group, and (v) a compound selected from the group consisting of 55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperidine;
F-1:3-[2'-(4"-Phenoxyphenoxy)ethoxyjpyridine;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine; and F-5: 3-(4'-Phenoxybenzyloxy)pyridine.
for use as a medicament for treating or preventing crustacean infestations in an aquatic animal.
In a still further aspect the invention provides a method of controlling crustacean infesta-tion of an aquatic animal, the method comprising administering to said animal or to the aquatic environment of the animal an effective amount of a juvenile hormone analogue compound including any of the above novel compounds.
There is also provided a pharmaceutical composition for controlling crustacean infestation of an aquatic animal, comprising a juvenile hormone analogue compound and at least one pharmaceutically acceptable carrier, and an aquatic animal feed composition comprising a juvenile hormone analogue compound.
DETAILED DISCLOSURE OF THE INVENTION
A major objective of the present invention is to provide improved means for controlling crustacean ectoparasitic infestations in aquatic animals such as fish. The invention is based on the finding that a range of compounds having juvenile hormone activity gener-ally referred to as juvenile hormone analogues (JHAs), which are known to have insect controlling activities including insecticidal activity, have a strong inhibiting effect on the metamorphosis of parasitic crustacean species resulting in a high mortality of these para-sites not only in vitro but also in vivo, i.e. when the parasites are attached to the host ani-mal, rendering such compounds potentially useful in the control of such ectoparasitic in-festations in live fish.
As used herein, the term "juvenile hormone analogue" indicates a synthetic compound that is structurally and/or functionally related to the naturally occurring juvenile hormones I, II and III, terpenoid substances that are found in insects where they regulate the devel-opment from the larval stage to the imago stage of the insects. Due to this juvenile hor-s move effect, JHAs are currently used as insect controlling agents (see e.g.
US 4,002,615 and 4,061,757). Juvenile hormone analogues are also referred to as juvenoids or juvenile hormone mimics.
In one aspect of the present invention there is provided the use of a compound having ju-venile hormone activity, in the manufacturing of a medicament for controlling crustacean infestation of aquatic animals.
Whereas other aquatic animals than fish may be infested by crustacean ectoparasites, the use according to the invention is particularly interesting for manufacturing medicaments for control of crustacean infestation in fish species having their natural habitat in cold, temperate or warm water environments. Thus, the medicament of the invention can be used therapeutically and/or prophylactically for controlling infestations in both wild and farmed fish including ornamental fish, occurring in freshwater, sea water or brackish wa-ter. Fish that can be treated with JHAs include any fish that can be infestated by ecto-parasitic crustaceans such as wild and farmed fish belonging to the Salmonidae family including, but not limited to Salmo salar, Salmo trutta, Salmo clarkii, Oncorhynchus gor buscha, Oncorhynchus keta, Oncorhynchus nekra, Oncorhynchus kisutch, Oncorhynchus tshawytscha, Oncorhynchus mason, Oncorhynchus mossambicus, Oncorhynchus mykiss and Salvelinus species. Other examples of fish where the JHAs can be used include carps, whitefish, roach, rudd, chub, sole, plaice, Japanese yellowtail, sea bass, sea bream, grey mullet, pompano, gilthread seabream, Tilapia spp., Cichlidae spp., cod, hali-but, wolf fish, flounder, aju and eel including Japanese eel.
Presently preferred target fish for the present invention include Atlantic salmon, Pacific salmon and trout.
It has been found that a large range of JHA compounds effectively control infestations by crustacean species generally referred to as sea lice such as Lepeophtheirus species.
However, as the metamorphosis processes are essentially the same in any crustacean species, it is envisaged that JHAs will be effective against other ectoparasitic crustacean species infestating aquatic animals. Such species are i.a. found in the following genera:
Ergasalus, Bromolochus, Chondracaushus, genera and species belonging to the Cope-pods class including the genera Caligus and Lepeophtheirus, Dichelestinum, Lambro-glenz, Hatschekia, Legophilus, Symphodus, Ceudrolasus, Pseudocycmus, Lernaea, Ler naeocera, Pennella, Achthares, Banasistes, Salmonicola, Brachiella, Epibrachiella, Pseu-dotracheliastes; and the families: Ergasilidae, Bromolochidae, Chondracanthidae, Caliji-dae, Dichelestiidae, Philichthyidae, Pseudocycnidae, Larnaeidae, Lernaepotidae, Sphyrii-dae, Cecorpidae, Branchiuriae (carp lice) with the family Argulidae that includes Argulus species.
In this context, important target species of crustaceans include Lepeophtheirus salmonis, Caligus elongatus and Anilocra physodes L, crustaceans of a species selected from the group consisting of an Anilocra species, a Chymothoa species, a Lironeca species, a Meinertia species, an Olencira species and a Bopyrus species and crustaceans of the Iso-pods class including Anilocra physodes, Chymothoa exigua, Lironeca califomica, Liro-neca convexa, Lironeca ovalis, Lironeca vulgaris, Meinertia oestroides, Meinertia parallels and Olencira praegustator.
In accordance with the invention, any compound having juvenile hormone activity, includ-ing a juvenile hormone analogue compound, that is effective with respect to retarding or inhibiting any stage of the development of crustaceans from the first larval stage to the pre-adult stage and/or which has a biological effect on any stage of the crustaceans in-cluding the adult stage is encompassed. Thus, a compound according to the invention that is capable of retarding or inhibiting at least one stage shift from the nauplius I stage through further nauplius stages, copepodite stages, chalimus stages, the pre-adult stage to the adult stage. Such compounds include juvenile hormone mimics such as epofe-nonane, phenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen and triprene, ju-venile hormones I, II and III, and the compounds disclosed in US 4,002,615 and 4,061,757. It should be understood that chitin synthesis inhibitors are not included in the above definition of compounds having juvenile hormone activity.
Also encompassed within the meaning of compounds having "juvenile hormone activity"
are compounds which prove to be positive when tested in a standard test system for evaluating compounds for juvenile hormone activity. Such standard tests, wherein Teni-brio mo/itortypically is applied as test organism, are well known in the art (se e.g. Slama et al., Insect Hormones and Bioanalogues, Springer-Verlag, New York 1974, p.
93).
Additionally, the below evaluation system for determining juvenile hormone activity can be 5 applied (adapted from "Methods used to evaluate candidate materials for juvenile hor-move activity", Pesticide Chemicals Research Branch, Beltsville, Maryland):
Juvenile hormone activity may be determined using newly-molted (4-8 hours) Tenibrio motitor pupae. The compounds to be evaluated are formulated to contain 10 Ng in 1 ml of 10 solution. Acetone is the preferred solvent and is used in both topical and vapor tests.
Topical application is with a micro applicator (Isco model M) fitted with a tuberculin syringe and a 27 gauge needle. One NI of the desired solution is administered/pupa on the venter of the last three abdominal segments. Vapor action is determined by applying the candi-date compound to the lower 1/3 of a 1 pint freezer type jar and then inverting the jar into a 1/2 pint container, containing 5 pupae. A dosage of 1 NI of the desired solution per pupa (5 NI/jar) is used. All pupae are held until the following molt to determine juvenile hormone activity, which is indicated by the presence of immature characters; e.g. i) retention of gin traps, ii) retention of gin traps and urogomphi, iii) retention of gin traps and urogomphi plus retention of pupal cuticle around area of treatment, and iv) 2nd pupae -retention of all pupal characters. If a perfect adult is obtained after molting, the compound has no ju-venile hormone activity. Farnesyl methyl ether is used as the standard for both topical and vapor tests.
In the present context, particularly interesting compounds having juvenile hormone activ-ity include:
(i) compounds of the general formula I
R1 X ~ ~ R2 Y Z
US 4,002,615 and 4,061,757). Juvenile hormone analogues are also referred to as juvenoids or juvenile hormone mimics.
In one aspect of the present invention there is provided the use of a compound having ju-venile hormone activity, in the manufacturing of a medicament for controlling crustacean infestation of aquatic animals.
Whereas other aquatic animals than fish may be infested by crustacean ectoparasites, the use according to the invention is particularly interesting for manufacturing medicaments for control of crustacean infestation in fish species having their natural habitat in cold, temperate or warm water environments. Thus, the medicament of the invention can be used therapeutically and/or prophylactically for controlling infestations in both wild and farmed fish including ornamental fish, occurring in freshwater, sea water or brackish wa-ter. Fish that can be treated with JHAs include any fish that can be infestated by ecto-parasitic crustaceans such as wild and farmed fish belonging to the Salmonidae family including, but not limited to Salmo salar, Salmo trutta, Salmo clarkii, Oncorhynchus gor buscha, Oncorhynchus keta, Oncorhynchus nekra, Oncorhynchus kisutch, Oncorhynchus tshawytscha, Oncorhynchus mason, Oncorhynchus mossambicus, Oncorhynchus mykiss and Salvelinus species. Other examples of fish where the JHAs can be used include carps, whitefish, roach, rudd, chub, sole, plaice, Japanese yellowtail, sea bass, sea bream, grey mullet, pompano, gilthread seabream, Tilapia spp., Cichlidae spp., cod, hali-but, wolf fish, flounder, aju and eel including Japanese eel.
Presently preferred target fish for the present invention include Atlantic salmon, Pacific salmon and trout.
It has been found that a large range of JHA compounds effectively control infestations by crustacean species generally referred to as sea lice such as Lepeophtheirus species.
However, as the metamorphosis processes are essentially the same in any crustacean species, it is envisaged that JHAs will be effective against other ectoparasitic crustacean species infestating aquatic animals. Such species are i.a. found in the following genera:
Ergasalus, Bromolochus, Chondracaushus, genera and species belonging to the Cope-pods class including the genera Caligus and Lepeophtheirus, Dichelestinum, Lambro-glenz, Hatschekia, Legophilus, Symphodus, Ceudrolasus, Pseudocycmus, Lernaea, Ler naeocera, Pennella, Achthares, Banasistes, Salmonicola, Brachiella, Epibrachiella, Pseu-dotracheliastes; and the families: Ergasilidae, Bromolochidae, Chondracanthidae, Caliji-dae, Dichelestiidae, Philichthyidae, Pseudocycnidae, Larnaeidae, Lernaepotidae, Sphyrii-dae, Cecorpidae, Branchiuriae (carp lice) with the family Argulidae that includes Argulus species.
In this context, important target species of crustaceans include Lepeophtheirus salmonis, Caligus elongatus and Anilocra physodes L, crustaceans of a species selected from the group consisting of an Anilocra species, a Chymothoa species, a Lironeca species, a Meinertia species, an Olencira species and a Bopyrus species and crustaceans of the Iso-pods class including Anilocra physodes, Chymothoa exigua, Lironeca califomica, Liro-neca convexa, Lironeca ovalis, Lironeca vulgaris, Meinertia oestroides, Meinertia parallels and Olencira praegustator.
In accordance with the invention, any compound having juvenile hormone activity, includ-ing a juvenile hormone analogue compound, that is effective with respect to retarding or inhibiting any stage of the development of crustaceans from the first larval stage to the pre-adult stage and/or which has a biological effect on any stage of the crustaceans in-cluding the adult stage is encompassed. Thus, a compound according to the invention that is capable of retarding or inhibiting at least one stage shift from the nauplius I stage through further nauplius stages, copepodite stages, chalimus stages, the pre-adult stage to the adult stage. Such compounds include juvenile hormone mimics such as epofe-nonane, phenoxycarb, hydroprene, kinoprene, methoprene, pyriproxyfen and triprene, ju-venile hormones I, II and III, and the compounds disclosed in US 4,002,615 and 4,061,757. It should be understood that chitin synthesis inhibitors are not included in the above definition of compounds having juvenile hormone activity.
Also encompassed within the meaning of compounds having "juvenile hormone activity"
are compounds which prove to be positive when tested in a standard test system for evaluating compounds for juvenile hormone activity. Such standard tests, wherein Teni-brio mo/itortypically is applied as test organism, are well known in the art (se e.g. Slama et al., Insect Hormones and Bioanalogues, Springer-Verlag, New York 1974, p.
93).
Additionally, the below evaluation system for determining juvenile hormone activity can be 5 applied (adapted from "Methods used to evaluate candidate materials for juvenile hor-move activity", Pesticide Chemicals Research Branch, Beltsville, Maryland):
Juvenile hormone activity may be determined using newly-molted (4-8 hours) Tenibrio motitor pupae. The compounds to be evaluated are formulated to contain 10 Ng in 1 ml of 10 solution. Acetone is the preferred solvent and is used in both topical and vapor tests.
Topical application is with a micro applicator (Isco model M) fitted with a tuberculin syringe and a 27 gauge needle. One NI of the desired solution is administered/pupa on the venter of the last three abdominal segments. Vapor action is determined by applying the candi-date compound to the lower 1/3 of a 1 pint freezer type jar and then inverting the jar into a 1/2 pint container, containing 5 pupae. A dosage of 1 NI of the desired solution per pupa (5 NI/jar) is used. All pupae are held until the following molt to determine juvenile hormone activity, which is indicated by the presence of immature characters; e.g. i) retention of gin traps, ii) retention of gin traps and urogomphi, iii) retention of gin traps and urogomphi plus retention of pupal cuticle around area of treatment, and iv) 2nd pupae -retention of all pupal characters. If a perfect adult is obtained after molting, the compound has no ju-venile hormone activity. Farnesyl methyl ether is used as the standard for both topical and vapor tests.
In the present context, particularly interesting compounds having juvenile hormone activ-ity include:
(i) compounds of the general formula I
R1 X ~ ~ R2 Y Z
where R' is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted iso-prenoid or alkoxy substituted alkyl, R2 is hydrogen or alkyl, X is oxygen, sulfur, methylene, carbinol or carbonyl, Y is nitrogen or methinine and Z is nitrogen, methine or nitrogen ox-ide;
(ii) compounds of general formula II
R~
where R' is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, RZ is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
\ \ ~Rz R~
where R' is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and Rz is methyl, ethyl or isopropyl, and (iv) a compound of the general formula IV
X Ar where X is oxygen or sulfur and Ar is a heteroaromatic group.
In this context, specific juvenile hormone analogue compounds (JHA ) include the follow-ing:
1: 5-(T-Ethoxy-3',T-dimethyloctyloxy)-2-methylpyridine;
2:5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
R-2: (3'R)-5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
S-2: (3'S)-5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
3: 2-Methyl-5-(T-methyloctyloxy)pyridine;
4: 2-Methyl-5-octyloxypyridine;
5:5-(3',7'-Dimethyloct-6'-enyloxy)-2-methylpyridine;
6: 5-(3',7'-Dimethylocta-2',6'-dienyloxy)-2-methylpyridine;
7: 5-(3',7'-Dimethylocta-2',6'-dienyloxy)pyridine;
8: 5-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-ethylpyridine;
9:5-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-methylpyridine;
10: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-ethylpyridine;
11: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-methylpyridine;
12: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpentyloxy]-2-methylpyridine;
(ii) compounds of general formula II
R~
where R' is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, RZ is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
\ \ ~Rz R~
where R' is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and Rz is methyl, ethyl or isopropyl, and (iv) a compound of the general formula IV
X Ar where X is oxygen or sulfur and Ar is a heteroaromatic group.
In this context, specific juvenile hormone analogue compounds (JHA ) include the follow-ing:
1: 5-(T-Ethoxy-3',T-dimethyloctyloxy)-2-methylpyridine;
2:5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
R-2: (3'R)-5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
S-2: (3'S)-5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
3: 2-Methyl-5-(T-methyloctyloxy)pyridine;
4: 2-Methyl-5-octyloxypyridine;
5:5-(3',7'-Dimethyloct-6'-enyloxy)-2-methylpyridine;
6: 5-(3',7'-Dimethylocta-2',6'-dienyloxy)-2-methylpyridine;
7: 5-(3',7'-Dimethylocta-2',6'-dienyloxy)pyridine;
8: 5-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-ethylpyridine;
9:5-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-methylpyridine;
10: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-ethylpyridine;
11: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-methylpyridine;
12: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpentyloxy]-2-methylpyridine;
13: 5-(3',T-Dimethyloctylsulfanyl)-2-methylpyridine;
14: 2-(3',T-Dimethylocta-2',6'-dienyloxy)pyridine;
15: 2-(3',7'-Dimethyloctylsulfanyl)pyridine;
16: 3-(3',T-Dimethyloctyloxy)-1-methylpiperidine;
17: 5-(3',7'-Dimethyloctyloxy)benzo[1,3]dioxole;
18: 5-(3',7'-Dimethylocta-2',6'-dienyloxy)benzo[1,3]dioxole;
19: 5-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzo[1,3]dioxole;
20: 5-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzo[1,3]dioxole;
21: 5-[5'-(2",2"-Dibromo-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzo[1,3]dioxole;
22: 5-(3',8'-Dimethylnona-2',6',7'-trienyloxy)benzo[1,3]dioxole;
23: 5-(3',7'-Dimethylocta-2',6'-dienylsulfanyl)benzo[1,3]dioxole;
24: 1-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-4-ethylbenzene;
25:1-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-ethylbenzene;
26: 1-[5'-(2",2"-Dibromo-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-ethylbenzene;
27: 1-(3',8'-Dimethylnona-2',6',7'-trienyloxy)-4-ethylbenzene;
28: Methyl 4-[5'-(2",2"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzoate;
29: Methyl4-[5'-(2",2"-dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzoate;
30: Methyl 4-(5'-(2",2"-dibromo-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzoate;
31: 1-Acetyl-4-[5'-(2",2"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzene;
32:1-Acetyl-4-[5'-(2",2"-dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy)benzene;
33: 1-Acetyl-4-[5'-(2", 2"-dibromo-3", 3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]benzene;
34: (3,7-Dimethyloctyloxy)benzene;
35:4-[5'-(2",2"-Dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-3-methoxybenzaldehyde;
36: 4-(5'-(2",2"-Dichloro-3", 3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-3-methoxybenzaldehyde;
37: 1-[5'-(2",2"-Dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-methoxy-4-propenylbenzene;
38:4-Allyl-1-[5'-(2",2"-dichloro-3",3"-dimethylcyclopropyl)-3'-methylpent-2'-enyloxy]-2-methoxybenzene;
39: Methyl 7,11-dimethyl-dodecc-2,4-dienoate;
40: Methyl 9-(2',2'-dimethylcyclopropyl)-7-methylnona-2,4-dienoate;
41: Ethyl 9-(2',2'-dimethylcyclopropyl)-7-methylnona-2,4-dienoate;
42:Isopropyl9-(2',2'-dimethylcyclopropyl)-7-methylnona-2,4-dienoate;
43: Methyl 9-(2',2'-dichloro-3',3'-dimethylcyclopropyl)-7-methylnona-2,4-dienoate;
44: Ethyl 9-(2',2'-dichloro-3',3'-dimethylcyclopropyl)-7-methylnona-2,4-dienoate;
45: Isopropyl 9-(2',2'-dichloro-3',3'-dimethylcyclopropyl)-7-methylnona-2,4-dienoate;
46: 2-Methyl-5-nonyloxypyridine;
47:2-Methyl-5-undecyloxypyridine;
48: 5-Dodecyloxy-2-methylpyridine;
49: 2-Methyl-5-(3',T,11'-trimethyldodeca-2',6',10'-trienyloxy)pyridine;
50: 5-(3',7'-Dimethyloctyloxy)-2-methylpyrimidine;
51: 3-(4',8'-Dimethylnonyl)pyridine;
52:3-(4',8'-Dimethylnonyl)pyridine-N-oxide;
53: 4,8-Dimethyl-1-pyridin-3-ylnonan-1-ol;
54: 4,8-Dimethyl-1-pyridin-3-ylnonan-1-one;
55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57:2-(3',T-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperazine;
59: 3-(3',7'-Dimethyloctyloxy)pyridine;
60: 3-(3',T-Dimethyloctylsulfanyl)pyridine;
61: (3',T-Dimethylocta-2',6'-dienyloxy)benzene;
F-1:3-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-2: 3-(T-Ethoxy-3',T-dimethyloctyloxy)pyridine;
F-3: Ethylcarbamic acid 2-(4'-phenoxyphenoxy) ethyl ester (phenoxycarb) ;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-5: 3-(4'-Phenoxybenzyloxy)pyridine;
methoprene; and hydroprene.
The fish or any other aquatic animal species can be treated orally, e.g. via their feed, or by bath treatment, e.g. in a medicinal bath where the fish are kept for a period of time (minutes to several hours) that provides a sufficient contact time to inhibit the parasitic crustaceans. Alternatively, it is possible to treat the biotope of the fish temporarily or con-tinuously, e.g. the net cages, entire ponds, aquaria, tanks or basins in which the fish are kept. It is a further suitable possibility to administer the compounds parenterally, e.g. by injection.
The active compounds are administered in medicament formulations which are adjusted to the applications. Formulations for oral administration include e.g.
powders, granulates, solutions, emulsifiable concentrates or suspension concentrates which are mixed homo-geneously as feed additives with the feed, or powders, granulates, emulsifiable concen-5 trates or suspension concentrates which are administered in the form of pills, the outer coat of which can consist e.g. of fish feed compositions which cover the active substance completely. Alternatively, the active substance may be applied onto the surface of feed particles such as pellets or granules, e.g. incorporated in a lipid component such as a fish oil.
Useful medicament formulations for bath application or for treating the biotope of the fish include powders, granulates, solutions, emulsions, micro-emulsions, suspensions, tablets or the active substance itself. The end-user may use these formulations in dilute or undi-lute form.
The active compound in any of these formulations may be used in pure form, as a solid active substance e.g. in a specific particle size, or together with at least one of the adju-vants that are conventionally used in formulation technology, such as extenders, typically solvents or solid carriers, or surface active compounds.
The formulations are prepared in a manner known per se, typically by mixing, granulating and/or compacting the active compound with solid or liquid carriers, where appropriate, with the addition of further auxiliary substances such as emulsifying or dispersing agents, solubilisers, colorants, antioxidants and/or preservatives.
It is also possible to use semi-solid formulations for the bath treatment. The active sub-stance, which is suspended or dissolved in oily or fatty matrices, is washed out on admini-stration. The release can be controlled by the choice of adjuvants, concentration of the ac-tive substance and form. Coprimates or melts of hard fats comprising the active sub-stance are also suitable for use.
The diluted compositions of this invention are generally prepared by contacting the active substance with liquid and/or solid formulation assistants by stepwise mixing and/or grind-ing such that an optimal development of the antiparasitic activity of the formulation is achieved that conforms with the application.
Formulation assistants can e.g. be solid carriers, solvents and, where appropriate, surface active substances which are non-toxic for marine fauna and flora.
The bath application of the medicament compositions of the invention to the parasites to be controlled can e.g. be carried out such that the compositions are placed in the cage in the form of solutions, emulsions, micro-emulsions, suspensions, powders or tablets, where they are dissolved or dispersed by the movement of the fish and the flow of the water. Concentrated compositions can also be diluted with large volumes of water before applied to the cages.
In one embodiment, micro-emulsions can advantageously be applied for bath application of the medicament compositions when using juvenile hormone analogues which are not water-soluble or have a low water-solubility. When such micro-emulsions, comprising ju-venile hormone analogues are added to the bath treatment water, a clear solution is typi-cally seen.
In one useful embodiment, the micro-emulsion comprises solvents, surfactants and stabi-lisers in addition to the juvenile hormone analogues. Preferably, no water should be pres-ent in the micro-emulsion.
Examples of solvents which can be applied in a micro-emulsion include acetone, mono-hydric, dihydric or polyhydric alcohol (including ethanol, polyethylene glycol, propylene glycol), glycerine, mineral oil, vegetable oils or oils of animal origin, fatty acid esters, di-methyl sulphoxid (DMSO), dioxan, tetrahydrofuran (THF), 2-pyrrolidon, N-methyl-pyrrolidon. Examples of suitable surfactants include acetylated mono-and diglycerides with fatty acids, polyacrylic copolymers, beeswax, lecithin, fatty acids, guar gum, xanthan gum, tragacanth gum, PEG linked with fatty acids or sugars, hydrogenated and etoxylated castor oil, cellulose derivatives, compounds consisting of fatty acids esterified to sugars, N-octyl-2-pyrrolidon, N-dodecyl-2-pyrrolidon, EO/PO blockpolymers and dodecylbenzene sulfonate salts. Examples of stabilisers include antioxidants, pH regulating compounds such as citric acid, and complexing agents.
In useful embodiments the micro-emulsion comprises: i) juvenile hormone analogues in an amount which is in the range of 0.1-10 wt% including the range of 0.5-5 wt%; ii) sol-vents in the range of 20-30 wt% including the range of 22-28 wt% such as in the range of 25-28 wt%; iii) surfactants in the range of 50-80 wt% including the range of 55-75 wt%
such as in the range of 60 to 70 wt%; and iv) stabilisers in the range of 0.1-5 wt% includ-ing the range of 0.5-5 wt% such as in the range of 1 to 2 wt%. One example of a specific composition of a micro-emulsion is given in the below examples.
In a further aspect the invention relates to novel juvenile hormone analogue compounds of the general formula I, the general formula II, the general formula III or of the general formula IV and the compounds 55-58, F-1, F-4 and F-5 as defined above, including a compound of the general formula II having saturated side chains to the aromatic ring, for use as a medicament for treating or preventing crustacean infestations in an aquatic ani-mal.
It is also a significant objective of the invention to provide a method of controlling infesta-tions with any of the above crustacean species in aquatic animals including fish of the species as mentioned above, the method comprising administering to said animal or to the aquatic environment of the animal an effective amount of a juvenile hormone ana-logue compound.
In the method of the invention any of the above juvenile hormone analogues including epofenonane, phenoxycarb, hydroprene, kinoprene, methoprene and triprene and the above compounds of the general formula I, the general formula II, the general formula III
or of the general formula IV as also defined above can be used as the antiparasitically ac-tive compound.
In this method, the active compound is administered by any of the above routes using the compound as such or in the form of a composition that is adjusted to the selected manner of administration, including compositions for bath treatment or addition to the biotope of animals or fish, compositions for oral administration, optionally via the feed, or injectable compositions. The amount of active substance in the administration form can vary de-pending i.a. on the dosage form, the target parasite, the age and condition of the fish to be treated.
When the compound is used as a medicament for bath treatment or as a composition that is added to the aquatic environment of the aquatic animal, the amount of the active juve-nile hormone analogue compound in the environment of the aquatic animal depends on the manner and duration of treatment and also on the age and condition of the fish to be treated. Effective dosages of the active substance in the water is generally in the range of 1 ppb to 1 ppm such as in the range of 10 ppb to 500 ppb including the range of 100 to 300 ppb. In one preferred embodiment, the compound is added the aquatic environment in the form of a micro-emulsion In accordance with the invention there is also provided a pharmaceutical composition for controlling crustacean infestation of an aquatic animal such as a fish, comprising a juve-nile hormone analogue compound and at least one pharmaceutically acceptable carrier.
In this context, suitable carriers include, but are not limited to, solid carriers such as e.g.
kaolin, talcum, bentonite, sodium chloride, calcium phosphate, carbohydrates, cellulose, cotton seed meal, polyethylene glycol ether and, if necessary, binders such as gelatine, soluble cellulose derivatives or surface active substances such as ionic or anionic dispers-ing agents.
As it is explained above, such a composition can e.g. be in the form of a powder, a granu-late, a suspension, an emulsion, a micro-emulsion and a solution or it can for certain pur-poses be in the form of an injectable composition. Deperiding on the intended application the composition of the invention may further comprise a component selected from the group consisting of a solvent, a wetting agent, an emulsifying agent, a bulking agent and a dispersing agent. Suitable solvents include aromatic hydrocarbons, alkylated naphtalenes, or tetrahydronaphtalenes, aliphatic or cycloaliphatic hydrocarbons such as paraffins or cyclohexane, alcohols such as ethanol, propanol or butanol, glycols and their esters and ethers, ketones such as acetone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide, water, as well as vegetable oils and oils of animal origin such as e.g.
fish oil.
Depending on the type of formulation, suitable surface active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties.
It will be appreciated that the composition of the invention can comprise two or more juve-nile hormone analogue compounds or it can comprise at least one further anti-parasitically active compound of any of the conventionally used types of antiparasitic substances in-cluding formaldehyde, hydrogen peroxide, a cholinesterase inhibitor such as e.g. metri-fonate or dichlorvos, an organophosphorus compound, a carbamate compound, a chitin inhibiting compound, an avermectin compound and/or a pyrethroid compound.
As it is mentioned above, one convenient manner of administering a juvenile hormone analogue compound to fish is to add the compound to the normal fish feed.
Accordingly, there is provided an aquatic animal feed composition comprising a juvenile hormone analogue compound as defined above, in an amount that will provide an antiparasitically active amount of the JH analogue compound in the fish. The active compound can be in-corporated in the feed in any of the above manners. The active compound can be mixed directly with the feed ingredient as such or it can be added in the form of a more or less concentrated feed additive composition. As an example such an additive composition can consist of 1-10 wt% of active compound, 49-90 wt% of a protein carrier such as soy bean protein, 0-50 wt% of ground calcium powder, 0-2 wt% of an alcohol, hydroxypropyl cellu-lose and water ad 100 wt%. Suitable forms of "medicated" feed comprising the JH ana-logue compound include granulated feed, pelleted feed and feed in the form of an emul-sion or micro-emulsion. The amount of the juvenile hormone analogue in feed composi-tions of the invention is typically in the range of 0.001 to 5 % wt% such as 0.01 to 3 wt%
including 0.1 to 1 wt%.
As it was described for the above composition of the invention, the feed composition of the invention can comprise two or more juvenile hormone analogue compounds or it can comprise at least one further anti-parasitically active compound of any of the convention-ally used types of antiparasitic substances including formaldehyde, hydrogen peroxide, a cholinesterase inhibitor such as e.g. metrifonate or dichlorvos, an organophosphorus compound, a carbamate compound, a chitin inhibiting compound, an avermectin com-pound and/or a pyrethroid compound.
The invention will now be further illustrated in the following non-limiting examples and in the drawing where Fig. 1 shows the percentage of copepodite larvae relative to the number of nauplius lar-vae exposed to compound 6 as defined herein [5-(3',T-Dimethylocta-2',6'-dienyloxy)-2-methylpyridinej at concentrations of 0.01 ppm, 0.05 ppm, 0.3 ppm and 1.0 ppm, respec-tively for 1, 5 and 24 hours, respectively (Example 3);
Fig. 2 shows the percentage of copepodite larvae relative to the number of nauplius lar-vae exposed to compound 7 as defined herein [5-(3',7'-Dimethylocta-2',6'-dienyloxy)pyridine] at concentrations of 0.3 ppm and 1.0 ppm for 1, 5 and 24 hours, re-5 spectively (Example 3);
Fig. 3 shows the percentage of copepodite larvae relative to the number of nauplius lar-vae exposed to compound 59 as defined herein [3-(3',T-Dimethyloctyloxy)pyridine;] at concentrations of 0.3 ppm and 1.0 ppm for 1, 5 and 24 hours, respectively (Example 3);
Fig. 4 shows the ratio between number of copepodites in groups of Lepeophtheirus sal-monis larvae exposed compounds 6, 7 or 59 for 1, 5 and 24 hours, respectively at con-centrations of 0.01 ppm, 0.05 ppm, 0.3 ppm and 1.0 ppm, respectively (Example 3). Data for these exposure periods were combined for each concentration and the controls for each compound were combined. A ratio of 1 indicates that the same number of copepo-dites were developed in the exposed groups and the control groups; and Fig. 5 summarises the results of the experiments in Example 4 where Lepeophfheirus sal-monis nauplius stage larvae were exposed for 24 hours to 1.0 ppm of compounds 4 [2-Methyl-5-octyloxypyridine], 2 [5-(3',T-Dimethyloctyloxy)-2-methylpyridine, 34 [(3,7-Dimethyloctyloxy)benzene], 17 [5-(3',T-Dimethyloctyloxy)benzo[1,3]dioxole] 60 [3-(3',7'-Dimethyloctylsulfanyl)pyridine] or 61 [(3',T-Dimethylocta-2',6'-dienyloxy)benzene].
EXAMPLES
In the following examples the effect of a range of juvenile hormone analogues on viability and metamorphosis of parasitic larval stages of crustacean species are reported. The fol-lowing compounds were tested:
4: 2-Methyl-5-octyloxypyridine;
2: 5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
6 = B: 5-(3'.T-Dimethylocta-2'.6'-dienyloxy)-2-methylpyridine;
7: 5-(3'.T-Dimethylocta-2'.6'-dienyloxy)pyridine;
14: 2-(3',7'-Dimethylocta-2',6'-dienyloxy)pyridine;
34: (3,7-Dimethyloctyloxy)benzene;
17: 5-(3',T-Dimethyloctyloxy)benzo;[1,3jdioxole;
60: 3-(3',7'-Dimethyloctylsulfanyl)pyridine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiopene;
1: 5-(T-Ethoxy-3',T-dimethyloctyloxy)-2-methylpyridine;
51: 3-(4',8'-Dimethylnonyl)pyridine;
50: 5-(3',T-Dimethyloctyloxy)-2-methylpyrimidine;
59: 3-(3',T-Dimethyloctyloxy)pyridine;
61: (3',T-Dimethylocta-2',6'-dienyloxy)benzene;
F-1:3-[2'-(4"-Phenoxyphenoxy)ethoxyjpyridine;
F-2: 3-(T-Ethoxy-3',7'-dimethyloctyloxy)pyridine;
F-3: Ethylcarbamic acid 2-(4'-phenoxyphenoxy) ethyl ester (phenoxycarb);
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxyjpyridine;
F-5 3-(4'-Phenoxybenzyloxy)pyridine;
AC = methoprene; and AD = hydroprene.
The effect of juvenile hormone (JH) analogue compounds on Lepeophtheirus salmonis larvae Nine JH analogue compounds designated 2, 6, 7, 14, 57, 1, 51, 50 and 59 (see above) were tested according to the following protocol:
Female sea lice with mature ovaries (dark pigmented) were collected in a tank containing 0.5 I sea water. Newly developed nauplius stage larvae were picked with a pipette or were separated from the water by filtration and used for further studies A large number of nauplii larvae (>100) in 300-400 ml aerated sea water were subjected to different JH analogues at a concentration of 3 ppm, and vitality and mortality of the nauplii monitored. The results of this experiment is summarized in Table 1.1.
Table 1.1. Effect on nauplius larvae of tested JH analogue compounds Compound Effect on nauplius Observation time (hours) larvae 57 no effect 48 14 no effect 20 2 Large proportion dead96 1 Large proportion dead96 51 Large proportion dead96 50 Large proportion dead96 7 All dead 5 6 All dead 24 59 All dead 15 The effect of the above compounds 6, 7 and 59 was further investigated at different con-centrations and the effect against sea lice was monitored. In the below Table 1.2 the fol lowing designations are used: +++ all nauplius larvae dead, ++ most nauplius larvae dead, + few dead nauplius larvae and - no dead nauplius larvae.
Table 1.2. Effect of compounds 6, 7 and 59 on nauplius larvae Compound ConcentrationObservation , time (hours) (ppm) 3 20 6 15.0 +++ +++
1.5 +++ +++
0.15 - ++
7 18.0 +++ +++
1, g ++ +++
x.18 - +
59 6.0 ++ +++
1.0 - +++
0.15 - -Among the tested compounds 6, 7 and 59 were the most effective against sea lice nau-plius larvae.
The effect of juvenile hormone analogues on the development of Lepeophtheirus sal-monis from nauplius stage to copepodite stage The JH analogue compounds 51, 1 and 50 were tested at a concentration of 0.7 ppm to determine their effect on the development from nauplius larvae to copepodites as com-pared to a control group not exposed to JH analogue. After 14 days of exposure the num-ber of copepodites were calculated. Most of the nauplius larvae in the control group de-veloped into copepodites. Larvae exposed to the compounds 51 and 50 showed results that were similar to the control. However, no copepodites were present in the group ex-posed to the compound 1, and only dead nauplius larvae were found.
The effect of JH analogue compounds 6, 7 and 59 on the development of Lepeophtheirus salmonis from nauplius stage to copepodite stage The apparently most effective compounds from Example 2 were selected for further inves-tigation. The effect of the compounds 6, 7 and 59 on the development from nauplius lar-vae to copepodites were tested at concentrations of 0.01 ppm, 0.05 ppm, 0.3 ppm and 1.0 ppm, respectively at the exposure periods of 1, 5 and 24 hours, respectively.
The number of nauplius and copepodite larvae were counted after 3-7 days. The experi-ments were run in triplicate at each concentration and each exposure period.
Additionally, control groups exposed to equivalent amount of acetone used as solvent for the test com-pounds were included.
The results of these experiments are summarised in Figures 1-4 It is concluded that the tested compounds showed high effect in respect of inhibiting the development from nauplius larval stage to copepodites. In particular, compound showed complete inhibition at 1.0 ppm and an exposure period of 24 hours. This com-pound also had a significant metamorphosis inhibiting effect at concentrations less than 1.0 ppm. Thus, at 0.01 ppm, 0.05 ppm and 0.3 ppm about 40% reduction in numbers of copepodites, relative to the controls, was observed The effect of compounds 4, 2, 34, 17, 60 and 61 on the development of Lepeophtheirus salmonis from nauplius stage to copepodite stage The compounds 4, 2, 34, 17, 60 and 61 were tested using the protocol as in Example 1 using exposure at 1.0 ppm for 24 hours. The results of this experiment are shown in Fig.
5. All of the tested compounds except compound 61 completely inhibited the development from the nauplius to the copepodite stage. The compound 60 were tested further at 1.0 ppm using an exposure period of only 1 hour. Under these conditions, the compound had a good effect in that only 7% of the larvae exposed developed into the copepodite stage.
The effects of compounds 6, F-1, F-2, F-3, F-4 and F-5 on Lepeophtheirus salmonis nau-plius larvae and the development of Lepeophtheirus salmonis from the nauplius stage to the copepodite stage The experiments were conducted essentially as in Example 2. 10-50 newly hatched nau-plius I larvae were placed in trays containing 50 ml of sea water (temperature 16-19°C, salinity 2.2%) to which the compound to be tested was added at 1.0 ppm and the expo-sure time was 24 hours following which the larvae were separated from the water and transferred to fresh sea water. After 3-5 days, the number of nauplii and copepodites were counted. Acetone was used as solvent for the compounds and the same volume of ace-tone was added to trays with control larvae. All experiments were carried out in triplicate or quadruplicate.
The results are summarised in Tables 5.1. and 5.2.
Table 5.1. No. of copepodites on day 4 after the exposure Experiment 1A Experiment 1 B
Compound Per cent copepodites Per cent copepodites 6 65.0 40.2 F-1 42.1 28.6 F-2 28.4 23.0 Control 56.6 36.8 The compounds F-1, F-2, F-3, F4 and F-5 were tested for their effect on nauplius stage larvae at a concentration of 1.0 ppm. The number of surviving and dead nauplii in the 5 trays were counted immediately after exposure.
Table 5.2. Effect of compounds F-1, F-2, F-3 F-4 and F-5 against nauplii and inhibition of development into the copepodite stage Compound % dead nauplii % copepodites 4 days after exposure F-5 85 _ __ - 0 Control 70 - 22 All of the tested compounds F-1 to F-5 showed a significant inhibition of development of nauplii into copepodites under the test conditions. Compounds F-1 and F-5 inhibited the development into copepodites completely and showed a high efficiency against nauplius larvae.
Screening of JHA compounds for sea lice larvicid effect The effect of 12 compounds designated A (= 59, B (= 6), C (= F-1), D (= F-3), E (= F-4) , F
(= F-5), G (=propoxur) , H (=bassa), I (=resmethrin), J (=deltamethrin), K
(=permethrin) and L (=agromazine), respectively on the survival of nauplius larval stages 1 and 2 of sea lice (Lepeophtheirus salmonis) was tested. The compounds designated G-L are not juve-nile hormone analogues, but are included for comparison. Survival, mortality and possible deformations on the larvae were recorded for each group 6 days after exposure to the test compounds for 24 hours.
Adult female sea lice with mature ovaries were collected and the ovaries were separated from the animals and incubated in running sea water at 8°C. By means of a pipette 30 newly hatched larvae at the nauplius 1 stage were transferred to 50 ml pure sea water in petri dishes. The respective test compounds dissolved in acetone were added to the dishes at a concentration of 1.0 ppm (50 ~I). The larvae were exposed for 24 hours before new fresh water was supplied. The water was changed daily during the test period. The experiments were done in triplicate. To one control group of larvae 50 p1 of acetone was added and another group was kept in pure sea water.
A considerable variation in survival and mortality for the test groups was observed, but the control groups were relatively similar. Data for survival and mortality are summarised in Table 6.1:
Table 6.1 Group 1. Live/dead 2. Live/dead 3. Live/dead larvae larvae larvae Control (water) 26/4 23/3 -Control (acetone)27/4 26/6 28/2 The compounds B, C, F, I and J had the best larvicidal effect on the sea lice larvae. None of the larvae reached the copepodite stage during the screening period. In the groups B
and C, the distribution of dead larvae were equal between nauplius stages 1 and 2. For the groups I, J and K, nauplius 1 larvae dominated among the dead larvae, whereas stage 2 nauplii dominated among the dead larvae in group F.
A common observation for groups C, I, J and K was that the dead larvae had protrusions (vacuoles) at the antenna region. It is possible that this is due to the fact that the larvae grow to a size that is to large for the shell resulting in rupture of the larvae.
The effect of JH analogues on development and survival of sea lice (Lepeophtheirus sal-monis) on sea water adapted Atlantic salmon (Salmo salary 7.1. Materials and methods Test compounds The commercial juvenile hormone analogue compound methoprene (AC) was tested.
Test fish The test fish were distributed into tanks of 500 I (45 fish per tank). Running sea water that was adjusted in respect of oxygen (at least 70% saturation in outlet water), salinity (34 promille) and temperature (11.5°C) was supplied to the tanks. The photoperiod was set at 18 hours of light and 6 hours of dark throughout the test period.
Bath experiment protocol For a 14 days bath regimen 9.239 ml of pure methoprene (AC) was mixed with 1,700 ml of acetone which gave a stock solution at 5,000 ppm compound AC, which was dosed over 14 days. The compound was added to the water at a concentration of 0.1 ppm.
Cultivation of L. salmonis Adult female sea lice with mature ovaries were collected and the ovaries were separated from the female sea lice and incubated in running sea water (salinity 34 promille) at 10°C.
Newly hatched nauplius larvae were harvested daily and transferred to trays to produce infective copepodite larvae.
Challenge with sea lice During exposure to the sea lice, the water supply was stopped and the tanks were ad-justed to about 100 I of water. About 2,000 two days old copepodites were distributed to each tank. During exposure the tanks were aerated. After 2 hours the tanks were filled and the water supply was stopped. The fish were exposed to copepodites in stagnant water for 12 hours under aeration before the usual water regimen was re-established.
Data recording Five days following copepodite exposure, the success of infestation was recorded on 5 fish from each tank and the medication regimen was initiated. In all tanks the number of sea lice was recorded 1, 5 and 10 days after termination of the medication period (10 fish). The distribution of the various stages of sea lice was recorded when the fish was removed from the tanks. The recording of the various chalimus stages was simplified by recording chalimus stages 1 and 2 as juvenile chalimus (ChJ) whereas chalimus 3 and 4 were recorded as "old" chalimus (ChG). The first and second pre-adult stages and the adult stage were also recorded.
7.2. Results Fish mortality No fish mortality was recorded throughout the entire test period.
Sea lice mortality: 14 days of bath treatment After 14 days of bath treatment with compound methoprene (AC), the fish had signifi-cantly less sea lice infestation than the corresponding control group (p<0.01 ) The effect of oral administration of JH analogue 59 on development and survival of sea lice-(Lepeophtheirus salmonis) on Atlantic salmon in sea water(Salmo salary Materials and methods Test compounds 10 The juvenile hormone analogue compound 59, 3-(3',7'-Dimethyloctyloxy)pyridine, was tested Test fish 15 400 Atlantic salmon of average weight 2.5 kg were distributed equally into two net pens (4x4x4 m) in a fish farm. The fish was deloused with NUVAN (dichlorvos) before the ex-periment. One group was used as a control and one group was treated with JH
analogue 59, 3-(3',7'-Dimethyloctyloxy)pyridine;, by oral administration. The fish farm was heavily infested with sea lice.
Preparation of feed containing JH analogue 59 Ordinary fish feed for Atlantic salmon (Felleskjopet) 12 mm was coated with JH
analogue 59, 3-(3',T-Dimethyloctyloxy)pyridine. The pure compound (liquid) was dissolved in Cape-line-oil to a concentration of 5.0% and then coated on feed pellet at a concentration of 10% oil. 9.4 kg feed coated with 59 was produced. The concentration was 5.0 g of sub-stance 59 per kg feed.
Oral administration of JH analogue.
Feed containing 59, 3-(3',T-Dimethyloctyloxy)pyridine, was fed on alternate days at a feeding rate of 0.5% per day. Ordinary feed was fed the days without medication and control fish was fed ordinary feed throughout the experiment. A total of 4 days of medica-tion was used and the total amount of 59, 3-(3',T-Dimethyloctyloxy)pyridine, applied was 20 gram per kg fish.
The fish was free of sea lice when the treatment started after the NUVAN
treatment Data recording In all net pens the number of sea lice was recorded 3 months after termination of the medication period (10 fish of each group). The distribution of the various stages of sea lice was recorded when the fish was removed from the net pens.
Results Fish mortality No fish mortality was recorded throughout the entire test period.
Table 8.1 Number of sea lice per fish 3 months after treatment 59, 3-(3',T-Dimethyloctyloxy)pyridine Control Fish no. Chalimus Pre-adultAdult ChalimusPre-adultAdult Average 12 18 32 23 23 52 Standard 6 23 15 11 9 23 deviation The number of sea lice at stages chalimus and adults are significantly lower in the group treated with JH analogue 59 than in the control group (a=0.05) The total average number of all sea lice stages in controls is 98 per fish while in the group treated with JH analogue 59 this number is reduced to 61. Because salmon in neighbour-ing cages were heavily infested with sea lice, migration of adult and pre-adult lice to the experimental groups occurred. The significant reduction in chalimus stages in the group treated with JH analogue 59 shows that development of copepodite through the four chalimus stages is inhibited by the treatment.
The effect of oral administration of JH analogues methoprene and hydroprene on devel-opment and survival of sea lice (Lepeophtheirus salmonis) on Atlantic salmon in sea wa-ter(Salmo salary Materials and methods Test compounds The juvenile hormone analogues methoprene (AC) and hydroprene (AD) were tested.
Test fish A number of 135 Atlantic salmon of average weight 117-145 grams was used in the ex-periment which took place in a fish disease facility. The test fish were distributed into tanks of 500 I with 45 fish per tank. Running sea water that was adjusted in respect of oxygen (at least 70% saturation in outlet water), salinity (34 promille) and temperature (11.5°C) was supplied to the tanks. The photoperiod was set at 18 hours of light and 6 hours of dark throughout the test period.
Preparation of feed containing the JH analogues methoprene (AC) and hydroprene (AD).
Ordinary fish feed for Atlantic salmon (Felleskjrapet) 3 mm was coated with the JH ana-logues methoprene (AC) and hydroprene (AD). The pure compounds were added to the feed in a mixer and then Capeline-oil was added to a concentration of 3.3%
while the mixer was running. 480 grams of medicated feed was made of each group. Two concen-trations of methoprene: 10 gram per kg feed (AC/X) and 2 gram per kg feed (AC/Y) were made. Also two concentrations of hydroprene (AD) were made: 10 gram per kg feed (AD/X) and 2 gram per kg feed (AD/Y) Cultivation of L. salmonis Adult female sea lice with mature ovaries were collected and the ovaries were separated from the female sea lice and incubated in running sea water (salinity 34 promille) at 10°C.
Newly hatched nauplius larvae were harvested daily and transferred to trays to produce infective copepodite larvae.
Challenge with sea lice During exposure to the sea lice, the water supply was stopped and the tanks were ad-justed to about 100 I of water. About 20,000 two days old copepodites were distributed to each tank. During exposure the tanks were aerated. After 2 hours the tanks were filled and the water supply was stopped. The fish were exposed to copepodites in stagnant water for 12 hours under aeration before the usual water regimen was re-established.
Oral administration of JH analogue Feed containing methoprene (AC/X and AC/Y) and hydroprene (AD/X and AD/Y) were fed at a feeding rate of 0.5% per day for 14 days. Control fish was fed ordinary feed through-out the experiment. A total of 371 gram of medicated feed was distributed to each medi-Gated fish group.
Data recording Five days following copepodite exposure, the success of infestation was recorded on 5 fish from each tank and the medication regimen was initiated. In all tanks the number of sea lice was recorded one day after termination of the medication period of 14 days (10 fish). The distribution of the various stages of sea lice was recorded. The recording of the various chalimus stages was simplified by recording chalimus stages 1 and 2 as juvenile chalimus (ChJ) whereas chalimus 3 and 4 were recorded as "old" chalimus (ChG).
The first and second pre-adult stages and the adult stage were also recorded.
Results Infection Due to a very high infestation rate of copepodites the number of sea lice attached to each fish was extremely high (> 100 per fish) and some mortality occurred among the fish.
The mortality of fish due to sea lice in the different groups is shown in Table 9.1:
Table 9.1 Tank Medication Mortality, number of fish out of 45 1 AC/X, 10 gram/kg, 14 6 days 2 AC/Y, 2 gram/kg, 14 5 days 3 Control fish 13 4 AD/X, 10 gram/kg, 14 1 days 5 AD/Y, 2 gram/kg, 14 5 days Highest mortality was observed in the control fish group which also had the largest num ber of sea lice (146 per fish). Lowest mortality was observed in the group medicated with hydroprene at highest concentration (AD/X) and which also had the lowest number of sea lice after medication (70 per fish).
Medication It was observed that the appetite was poor during feeding of medicated feed and that lots of medicated feed was not eaten. At sampling the day after medication only control fish 5 had feed pellets in the stomach. The reason for less intake of medicated feed could be due to taste problems. The actual dose of substance AC and AD presented for the fish is then considerably lower than the theoretical amounts. This is further supported by the fact that the average weight of medicated fish dropped during medication: AC/X from 142 to 123 gram, AC/Y from 145 to 117 gram, AD/X from 130 to 119 gram and AD/Y from 141 to 10 138 gram. The average weight of control fish increased slightly in the same period from 117 to 128 gram.
An ANOVA analysis of the number of sea lice per fish before medication and one day af-ter medication was performed, and the results are shown in the below Table 9.2.
Table 9.2 Tank Medication Number of Number of % change ANOVA signifi-sea sea in sea lice Ch.J lice pre-adultlice numbercance of be- reduc-fore medics-after medicationfrom beforetion to tion after medication 1 AC/X, 10 173 (n=5) 115 (n=10) 34 Yes, p =0.01 gram/kg, 14 days 2 AC/Y, 2 gram/kg,171 (n=5) 109 (n=10) 36 Yes, p=0.01 14 days 3 Control fish160 (n=5) 146 (n=5) 9 No 4 AD/X, 10 109 (n=5) 70 (n=10) 36 Yes, p <
gram/kg, 0.00001 14 days 5 AD/Y, 2 gram/kg,154 (n=5) 125 (n=10) 19 No 14 days The ANOVA analysis of the above data in Table 9.2 show that there are no significant re-duction of sea lice in the control fish group and in the AD/Y group, while the groups methoprene AC/X, AC/Y and hydroprene AD/X experienced a significant reduction of sea lice during medication.
A dose relation is seen with hydroprene in that the largest reduction in sea lice is ob-served with the highest concentration of hydroprene (AD/X).
The benefit of the administration of the JH analogues methoprene and hydroprene was clearly demonstrated by the lowering of the number of fish that died from sea lice infesta-tion and by the significant reduction in sea lice numbers.
Micro-emulsion concentrate for juvenile hormone analogues In the below Table 10.1 is given an example of a base micro-emulsion concentrate for bath treatment of fish with a juvenile hormone analogue.
The micro-emulsion is prepared in a tank kept at a constant temperature of 30°C, by adding the juvenile hormone analogue to the solvents (N-metyl-2-pyrrolidon and N-octyl-2-pyrrolidon) while stirring; and subsequently adding the remaining components (polyok-syl 35 castor oil, tetrapropylene benzenesulfonate Ca-salt and citric acid) to the mixture.
In bath treatment of fish, the juvenile hormone analogue is typically applied at concentra-tion of 0.1 to 1 ppm. I order to prepare a treatment bath of 100 m3 of water with a juvenile hormone analogue concentration of 0.1 ppm, 0.2 litre of micro-emulsion concentrate (stock solution) containing 50g juvenile hormone analogue per kg is added to the 100m3 of water. This micro-emulsion concentrate comprising the juvenile hormone analogue, can advantageously be diluted in a volume of water, e.g. 10 litres, before it is added to the aquatic environment wherein the fish to be treated is kept. A clear solution is seen when the micro-emulsion comprising the juvenile hormone analogue is added to the water.
Table 10.1 Micro-emulsion concentrate N-metyl-2-pyrrolidon 26.00 Kg N-octyl-2-pyrrolidon 25.00 Kg Polyoksyl 35 castor oil 41.00 Kg Tetrapropylene benzenesulfonate2.00 Kg Ca-salt Citric acid 1.00 Kg Juvenile hormone analogue 5.00 Kg Total 100.00 Kg
F-1:3-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-2: 3-(T-Ethoxy-3',T-dimethyloctyloxy)pyridine;
F-3: Ethylcarbamic acid 2-(4'-phenoxyphenoxy) ethyl ester (phenoxycarb) ;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-5: 3-(4'-Phenoxybenzyloxy)pyridine;
methoprene; and hydroprene.
The fish or any other aquatic animal species can be treated orally, e.g. via their feed, or by bath treatment, e.g. in a medicinal bath where the fish are kept for a period of time (minutes to several hours) that provides a sufficient contact time to inhibit the parasitic crustaceans. Alternatively, it is possible to treat the biotope of the fish temporarily or con-tinuously, e.g. the net cages, entire ponds, aquaria, tanks or basins in which the fish are kept. It is a further suitable possibility to administer the compounds parenterally, e.g. by injection.
The active compounds are administered in medicament formulations which are adjusted to the applications. Formulations for oral administration include e.g.
powders, granulates, solutions, emulsifiable concentrates or suspension concentrates which are mixed homo-geneously as feed additives with the feed, or powders, granulates, emulsifiable concen-5 trates or suspension concentrates which are administered in the form of pills, the outer coat of which can consist e.g. of fish feed compositions which cover the active substance completely. Alternatively, the active substance may be applied onto the surface of feed particles such as pellets or granules, e.g. incorporated in a lipid component such as a fish oil.
Useful medicament formulations for bath application or for treating the biotope of the fish include powders, granulates, solutions, emulsions, micro-emulsions, suspensions, tablets or the active substance itself. The end-user may use these formulations in dilute or undi-lute form.
The active compound in any of these formulations may be used in pure form, as a solid active substance e.g. in a specific particle size, or together with at least one of the adju-vants that are conventionally used in formulation technology, such as extenders, typically solvents or solid carriers, or surface active compounds.
The formulations are prepared in a manner known per se, typically by mixing, granulating and/or compacting the active compound with solid or liquid carriers, where appropriate, with the addition of further auxiliary substances such as emulsifying or dispersing agents, solubilisers, colorants, antioxidants and/or preservatives.
It is also possible to use semi-solid formulations for the bath treatment. The active sub-stance, which is suspended or dissolved in oily or fatty matrices, is washed out on admini-stration. The release can be controlled by the choice of adjuvants, concentration of the ac-tive substance and form. Coprimates or melts of hard fats comprising the active sub-stance are also suitable for use.
The diluted compositions of this invention are generally prepared by contacting the active substance with liquid and/or solid formulation assistants by stepwise mixing and/or grind-ing such that an optimal development of the antiparasitic activity of the formulation is achieved that conforms with the application.
Formulation assistants can e.g. be solid carriers, solvents and, where appropriate, surface active substances which are non-toxic for marine fauna and flora.
The bath application of the medicament compositions of the invention to the parasites to be controlled can e.g. be carried out such that the compositions are placed in the cage in the form of solutions, emulsions, micro-emulsions, suspensions, powders or tablets, where they are dissolved or dispersed by the movement of the fish and the flow of the water. Concentrated compositions can also be diluted with large volumes of water before applied to the cages.
In one embodiment, micro-emulsions can advantageously be applied for bath application of the medicament compositions when using juvenile hormone analogues which are not water-soluble or have a low water-solubility. When such micro-emulsions, comprising ju-venile hormone analogues are added to the bath treatment water, a clear solution is typi-cally seen.
In one useful embodiment, the micro-emulsion comprises solvents, surfactants and stabi-lisers in addition to the juvenile hormone analogues. Preferably, no water should be pres-ent in the micro-emulsion.
Examples of solvents which can be applied in a micro-emulsion include acetone, mono-hydric, dihydric or polyhydric alcohol (including ethanol, polyethylene glycol, propylene glycol), glycerine, mineral oil, vegetable oils or oils of animal origin, fatty acid esters, di-methyl sulphoxid (DMSO), dioxan, tetrahydrofuran (THF), 2-pyrrolidon, N-methyl-pyrrolidon. Examples of suitable surfactants include acetylated mono-and diglycerides with fatty acids, polyacrylic copolymers, beeswax, lecithin, fatty acids, guar gum, xanthan gum, tragacanth gum, PEG linked with fatty acids or sugars, hydrogenated and etoxylated castor oil, cellulose derivatives, compounds consisting of fatty acids esterified to sugars, N-octyl-2-pyrrolidon, N-dodecyl-2-pyrrolidon, EO/PO blockpolymers and dodecylbenzene sulfonate salts. Examples of stabilisers include antioxidants, pH regulating compounds such as citric acid, and complexing agents.
In useful embodiments the micro-emulsion comprises: i) juvenile hormone analogues in an amount which is in the range of 0.1-10 wt% including the range of 0.5-5 wt%; ii) sol-vents in the range of 20-30 wt% including the range of 22-28 wt% such as in the range of 25-28 wt%; iii) surfactants in the range of 50-80 wt% including the range of 55-75 wt%
such as in the range of 60 to 70 wt%; and iv) stabilisers in the range of 0.1-5 wt% includ-ing the range of 0.5-5 wt% such as in the range of 1 to 2 wt%. One example of a specific composition of a micro-emulsion is given in the below examples.
In a further aspect the invention relates to novel juvenile hormone analogue compounds of the general formula I, the general formula II, the general formula III or of the general formula IV and the compounds 55-58, F-1, F-4 and F-5 as defined above, including a compound of the general formula II having saturated side chains to the aromatic ring, for use as a medicament for treating or preventing crustacean infestations in an aquatic ani-mal.
It is also a significant objective of the invention to provide a method of controlling infesta-tions with any of the above crustacean species in aquatic animals including fish of the species as mentioned above, the method comprising administering to said animal or to the aquatic environment of the animal an effective amount of a juvenile hormone ana-logue compound.
In the method of the invention any of the above juvenile hormone analogues including epofenonane, phenoxycarb, hydroprene, kinoprene, methoprene and triprene and the above compounds of the general formula I, the general formula II, the general formula III
or of the general formula IV as also defined above can be used as the antiparasitically ac-tive compound.
In this method, the active compound is administered by any of the above routes using the compound as such or in the form of a composition that is adjusted to the selected manner of administration, including compositions for bath treatment or addition to the biotope of animals or fish, compositions for oral administration, optionally via the feed, or injectable compositions. The amount of active substance in the administration form can vary de-pending i.a. on the dosage form, the target parasite, the age and condition of the fish to be treated.
When the compound is used as a medicament for bath treatment or as a composition that is added to the aquatic environment of the aquatic animal, the amount of the active juve-nile hormone analogue compound in the environment of the aquatic animal depends on the manner and duration of treatment and also on the age and condition of the fish to be treated. Effective dosages of the active substance in the water is generally in the range of 1 ppb to 1 ppm such as in the range of 10 ppb to 500 ppb including the range of 100 to 300 ppb. In one preferred embodiment, the compound is added the aquatic environment in the form of a micro-emulsion In accordance with the invention there is also provided a pharmaceutical composition for controlling crustacean infestation of an aquatic animal such as a fish, comprising a juve-nile hormone analogue compound and at least one pharmaceutically acceptable carrier.
In this context, suitable carriers include, but are not limited to, solid carriers such as e.g.
kaolin, talcum, bentonite, sodium chloride, calcium phosphate, carbohydrates, cellulose, cotton seed meal, polyethylene glycol ether and, if necessary, binders such as gelatine, soluble cellulose derivatives or surface active substances such as ionic or anionic dispers-ing agents.
As it is explained above, such a composition can e.g. be in the form of a powder, a granu-late, a suspension, an emulsion, a micro-emulsion and a solution or it can for certain pur-poses be in the form of an injectable composition. Deperiding on the intended application the composition of the invention may further comprise a component selected from the group consisting of a solvent, a wetting agent, an emulsifying agent, a bulking agent and a dispersing agent. Suitable solvents include aromatic hydrocarbons, alkylated naphtalenes, or tetrahydronaphtalenes, aliphatic or cycloaliphatic hydrocarbons such as paraffins or cyclohexane, alcohols such as ethanol, propanol or butanol, glycols and their esters and ethers, ketones such as acetone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide, water, as well as vegetable oils and oils of animal origin such as e.g.
fish oil.
Depending on the type of formulation, suitable surface active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and/or wetting properties.
It will be appreciated that the composition of the invention can comprise two or more juve-nile hormone analogue compounds or it can comprise at least one further anti-parasitically active compound of any of the conventionally used types of antiparasitic substances in-cluding formaldehyde, hydrogen peroxide, a cholinesterase inhibitor such as e.g. metri-fonate or dichlorvos, an organophosphorus compound, a carbamate compound, a chitin inhibiting compound, an avermectin compound and/or a pyrethroid compound.
As it is mentioned above, one convenient manner of administering a juvenile hormone analogue compound to fish is to add the compound to the normal fish feed.
Accordingly, there is provided an aquatic animal feed composition comprising a juvenile hormone analogue compound as defined above, in an amount that will provide an antiparasitically active amount of the JH analogue compound in the fish. The active compound can be in-corporated in the feed in any of the above manners. The active compound can be mixed directly with the feed ingredient as such or it can be added in the form of a more or less concentrated feed additive composition. As an example such an additive composition can consist of 1-10 wt% of active compound, 49-90 wt% of a protein carrier such as soy bean protein, 0-50 wt% of ground calcium powder, 0-2 wt% of an alcohol, hydroxypropyl cellu-lose and water ad 100 wt%. Suitable forms of "medicated" feed comprising the JH ana-logue compound include granulated feed, pelleted feed and feed in the form of an emul-sion or micro-emulsion. The amount of the juvenile hormone analogue in feed composi-tions of the invention is typically in the range of 0.001 to 5 % wt% such as 0.01 to 3 wt%
including 0.1 to 1 wt%.
As it was described for the above composition of the invention, the feed composition of the invention can comprise two or more juvenile hormone analogue compounds or it can comprise at least one further anti-parasitically active compound of any of the convention-ally used types of antiparasitic substances including formaldehyde, hydrogen peroxide, a cholinesterase inhibitor such as e.g. metrifonate or dichlorvos, an organophosphorus compound, a carbamate compound, a chitin inhibiting compound, an avermectin com-pound and/or a pyrethroid compound.
The invention will now be further illustrated in the following non-limiting examples and in the drawing where Fig. 1 shows the percentage of copepodite larvae relative to the number of nauplius lar-vae exposed to compound 6 as defined herein [5-(3',T-Dimethylocta-2',6'-dienyloxy)-2-methylpyridinej at concentrations of 0.01 ppm, 0.05 ppm, 0.3 ppm and 1.0 ppm, respec-tively for 1, 5 and 24 hours, respectively (Example 3);
Fig. 2 shows the percentage of copepodite larvae relative to the number of nauplius lar-vae exposed to compound 7 as defined herein [5-(3',7'-Dimethylocta-2',6'-dienyloxy)pyridine] at concentrations of 0.3 ppm and 1.0 ppm for 1, 5 and 24 hours, re-5 spectively (Example 3);
Fig. 3 shows the percentage of copepodite larvae relative to the number of nauplius lar-vae exposed to compound 59 as defined herein [3-(3',T-Dimethyloctyloxy)pyridine;] at concentrations of 0.3 ppm and 1.0 ppm for 1, 5 and 24 hours, respectively (Example 3);
Fig. 4 shows the ratio between number of copepodites in groups of Lepeophtheirus sal-monis larvae exposed compounds 6, 7 or 59 for 1, 5 and 24 hours, respectively at con-centrations of 0.01 ppm, 0.05 ppm, 0.3 ppm and 1.0 ppm, respectively (Example 3). Data for these exposure periods were combined for each concentration and the controls for each compound were combined. A ratio of 1 indicates that the same number of copepo-dites were developed in the exposed groups and the control groups; and Fig. 5 summarises the results of the experiments in Example 4 where Lepeophfheirus sal-monis nauplius stage larvae were exposed for 24 hours to 1.0 ppm of compounds 4 [2-Methyl-5-octyloxypyridine], 2 [5-(3',T-Dimethyloctyloxy)-2-methylpyridine, 34 [(3,7-Dimethyloctyloxy)benzene], 17 [5-(3',T-Dimethyloctyloxy)benzo[1,3]dioxole] 60 [3-(3',7'-Dimethyloctylsulfanyl)pyridine] or 61 [(3',T-Dimethylocta-2',6'-dienyloxy)benzene].
EXAMPLES
In the following examples the effect of a range of juvenile hormone analogues on viability and metamorphosis of parasitic larval stages of crustacean species are reported. The fol-lowing compounds were tested:
4: 2-Methyl-5-octyloxypyridine;
2: 5-(3',7'-Dimethyloctyloxy)-2-methylpyridine;
6 = B: 5-(3'.T-Dimethylocta-2'.6'-dienyloxy)-2-methylpyridine;
7: 5-(3'.T-Dimethylocta-2'.6'-dienyloxy)pyridine;
14: 2-(3',7'-Dimethylocta-2',6'-dienyloxy)pyridine;
34: (3,7-Dimethyloctyloxy)benzene;
17: 5-(3',T-Dimethyloctyloxy)benzo;[1,3jdioxole;
60: 3-(3',7'-Dimethyloctylsulfanyl)pyridine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiopene;
1: 5-(T-Ethoxy-3',T-dimethyloctyloxy)-2-methylpyridine;
51: 3-(4',8'-Dimethylnonyl)pyridine;
50: 5-(3',T-Dimethyloctyloxy)-2-methylpyrimidine;
59: 3-(3',T-Dimethyloctyloxy)pyridine;
61: (3',T-Dimethylocta-2',6'-dienyloxy)benzene;
F-1:3-[2'-(4"-Phenoxyphenoxy)ethoxyjpyridine;
F-2: 3-(T-Ethoxy-3',7'-dimethyloctyloxy)pyridine;
F-3: Ethylcarbamic acid 2-(4'-phenoxyphenoxy) ethyl ester (phenoxycarb);
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxyjpyridine;
F-5 3-(4'-Phenoxybenzyloxy)pyridine;
AC = methoprene; and AD = hydroprene.
The effect of juvenile hormone (JH) analogue compounds on Lepeophtheirus salmonis larvae Nine JH analogue compounds designated 2, 6, 7, 14, 57, 1, 51, 50 and 59 (see above) were tested according to the following protocol:
Female sea lice with mature ovaries (dark pigmented) were collected in a tank containing 0.5 I sea water. Newly developed nauplius stage larvae were picked with a pipette or were separated from the water by filtration and used for further studies A large number of nauplii larvae (>100) in 300-400 ml aerated sea water were subjected to different JH analogues at a concentration of 3 ppm, and vitality and mortality of the nauplii monitored. The results of this experiment is summarized in Table 1.1.
Table 1.1. Effect on nauplius larvae of tested JH analogue compounds Compound Effect on nauplius Observation time (hours) larvae 57 no effect 48 14 no effect 20 2 Large proportion dead96 1 Large proportion dead96 51 Large proportion dead96 50 Large proportion dead96 7 All dead 5 6 All dead 24 59 All dead 15 The effect of the above compounds 6, 7 and 59 was further investigated at different con-centrations and the effect against sea lice was monitored. In the below Table 1.2 the fol lowing designations are used: +++ all nauplius larvae dead, ++ most nauplius larvae dead, + few dead nauplius larvae and - no dead nauplius larvae.
Table 1.2. Effect of compounds 6, 7 and 59 on nauplius larvae Compound ConcentrationObservation , time (hours) (ppm) 3 20 6 15.0 +++ +++
1.5 +++ +++
0.15 - ++
7 18.0 +++ +++
1, g ++ +++
x.18 - +
59 6.0 ++ +++
1.0 - +++
0.15 - -Among the tested compounds 6, 7 and 59 were the most effective against sea lice nau-plius larvae.
The effect of juvenile hormone analogues on the development of Lepeophtheirus sal-monis from nauplius stage to copepodite stage The JH analogue compounds 51, 1 and 50 were tested at a concentration of 0.7 ppm to determine their effect on the development from nauplius larvae to copepodites as com-pared to a control group not exposed to JH analogue. After 14 days of exposure the num-ber of copepodites were calculated. Most of the nauplius larvae in the control group de-veloped into copepodites. Larvae exposed to the compounds 51 and 50 showed results that were similar to the control. However, no copepodites were present in the group ex-posed to the compound 1, and only dead nauplius larvae were found.
The effect of JH analogue compounds 6, 7 and 59 on the development of Lepeophtheirus salmonis from nauplius stage to copepodite stage The apparently most effective compounds from Example 2 were selected for further inves-tigation. The effect of the compounds 6, 7 and 59 on the development from nauplius lar-vae to copepodites were tested at concentrations of 0.01 ppm, 0.05 ppm, 0.3 ppm and 1.0 ppm, respectively at the exposure periods of 1, 5 and 24 hours, respectively.
The number of nauplius and copepodite larvae were counted after 3-7 days. The experi-ments were run in triplicate at each concentration and each exposure period.
Additionally, control groups exposed to equivalent amount of acetone used as solvent for the test com-pounds were included.
The results of these experiments are summarised in Figures 1-4 It is concluded that the tested compounds showed high effect in respect of inhibiting the development from nauplius larval stage to copepodites. In particular, compound showed complete inhibition at 1.0 ppm and an exposure period of 24 hours. This com-pound also had a significant metamorphosis inhibiting effect at concentrations less than 1.0 ppm. Thus, at 0.01 ppm, 0.05 ppm and 0.3 ppm about 40% reduction in numbers of copepodites, relative to the controls, was observed The effect of compounds 4, 2, 34, 17, 60 and 61 on the development of Lepeophtheirus salmonis from nauplius stage to copepodite stage The compounds 4, 2, 34, 17, 60 and 61 were tested using the protocol as in Example 1 using exposure at 1.0 ppm for 24 hours. The results of this experiment are shown in Fig.
5. All of the tested compounds except compound 61 completely inhibited the development from the nauplius to the copepodite stage. The compound 60 were tested further at 1.0 ppm using an exposure period of only 1 hour. Under these conditions, the compound had a good effect in that only 7% of the larvae exposed developed into the copepodite stage.
The effects of compounds 6, F-1, F-2, F-3, F-4 and F-5 on Lepeophtheirus salmonis nau-plius larvae and the development of Lepeophtheirus salmonis from the nauplius stage to the copepodite stage The experiments were conducted essentially as in Example 2. 10-50 newly hatched nau-plius I larvae were placed in trays containing 50 ml of sea water (temperature 16-19°C, salinity 2.2%) to which the compound to be tested was added at 1.0 ppm and the expo-sure time was 24 hours following which the larvae were separated from the water and transferred to fresh sea water. After 3-5 days, the number of nauplii and copepodites were counted. Acetone was used as solvent for the compounds and the same volume of ace-tone was added to trays with control larvae. All experiments were carried out in triplicate or quadruplicate.
The results are summarised in Tables 5.1. and 5.2.
Table 5.1. No. of copepodites on day 4 after the exposure Experiment 1A Experiment 1 B
Compound Per cent copepodites Per cent copepodites 6 65.0 40.2 F-1 42.1 28.6 F-2 28.4 23.0 Control 56.6 36.8 The compounds F-1, F-2, F-3, F4 and F-5 were tested for their effect on nauplius stage larvae at a concentration of 1.0 ppm. The number of surviving and dead nauplii in the 5 trays were counted immediately after exposure.
Table 5.2. Effect of compounds F-1, F-2, F-3 F-4 and F-5 against nauplii and inhibition of development into the copepodite stage Compound % dead nauplii % copepodites 4 days after exposure F-5 85 _ __ - 0 Control 70 - 22 All of the tested compounds F-1 to F-5 showed a significant inhibition of development of nauplii into copepodites under the test conditions. Compounds F-1 and F-5 inhibited the development into copepodites completely and showed a high efficiency against nauplius larvae.
Screening of JHA compounds for sea lice larvicid effect The effect of 12 compounds designated A (= 59, B (= 6), C (= F-1), D (= F-3), E (= F-4) , F
(= F-5), G (=propoxur) , H (=bassa), I (=resmethrin), J (=deltamethrin), K
(=permethrin) and L (=agromazine), respectively on the survival of nauplius larval stages 1 and 2 of sea lice (Lepeophtheirus salmonis) was tested. The compounds designated G-L are not juve-nile hormone analogues, but are included for comparison. Survival, mortality and possible deformations on the larvae were recorded for each group 6 days after exposure to the test compounds for 24 hours.
Adult female sea lice with mature ovaries were collected and the ovaries were separated from the animals and incubated in running sea water at 8°C. By means of a pipette 30 newly hatched larvae at the nauplius 1 stage were transferred to 50 ml pure sea water in petri dishes. The respective test compounds dissolved in acetone were added to the dishes at a concentration of 1.0 ppm (50 ~I). The larvae were exposed for 24 hours before new fresh water was supplied. The water was changed daily during the test period. The experiments were done in triplicate. To one control group of larvae 50 p1 of acetone was added and another group was kept in pure sea water.
A considerable variation in survival and mortality for the test groups was observed, but the control groups were relatively similar. Data for survival and mortality are summarised in Table 6.1:
Table 6.1 Group 1. Live/dead 2. Live/dead 3. Live/dead larvae larvae larvae Control (water) 26/4 23/3 -Control (acetone)27/4 26/6 28/2 The compounds B, C, F, I and J had the best larvicidal effect on the sea lice larvae. None of the larvae reached the copepodite stage during the screening period. In the groups B
and C, the distribution of dead larvae were equal between nauplius stages 1 and 2. For the groups I, J and K, nauplius 1 larvae dominated among the dead larvae, whereas stage 2 nauplii dominated among the dead larvae in group F.
A common observation for groups C, I, J and K was that the dead larvae had protrusions (vacuoles) at the antenna region. It is possible that this is due to the fact that the larvae grow to a size that is to large for the shell resulting in rupture of the larvae.
The effect of JH analogues on development and survival of sea lice (Lepeophtheirus sal-monis) on sea water adapted Atlantic salmon (Salmo salary 7.1. Materials and methods Test compounds The commercial juvenile hormone analogue compound methoprene (AC) was tested.
Test fish The test fish were distributed into tanks of 500 I (45 fish per tank). Running sea water that was adjusted in respect of oxygen (at least 70% saturation in outlet water), salinity (34 promille) and temperature (11.5°C) was supplied to the tanks. The photoperiod was set at 18 hours of light and 6 hours of dark throughout the test period.
Bath experiment protocol For a 14 days bath regimen 9.239 ml of pure methoprene (AC) was mixed with 1,700 ml of acetone which gave a stock solution at 5,000 ppm compound AC, which was dosed over 14 days. The compound was added to the water at a concentration of 0.1 ppm.
Cultivation of L. salmonis Adult female sea lice with mature ovaries were collected and the ovaries were separated from the female sea lice and incubated in running sea water (salinity 34 promille) at 10°C.
Newly hatched nauplius larvae were harvested daily and transferred to trays to produce infective copepodite larvae.
Challenge with sea lice During exposure to the sea lice, the water supply was stopped and the tanks were ad-justed to about 100 I of water. About 2,000 two days old copepodites were distributed to each tank. During exposure the tanks were aerated. After 2 hours the tanks were filled and the water supply was stopped. The fish were exposed to copepodites in stagnant water for 12 hours under aeration before the usual water regimen was re-established.
Data recording Five days following copepodite exposure, the success of infestation was recorded on 5 fish from each tank and the medication regimen was initiated. In all tanks the number of sea lice was recorded 1, 5 and 10 days after termination of the medication period (10 fish). The distribution of the various stages of sea lice was recorded when the fish was removed from the tanks. The recording of the various chalimus stages was simplified by recording chalimus stages 1 and 2 as juvenile chalimus (ChJ) whereas chalimus 3 and 4 were recorded as "old" chalimus (ChG). The first and second pre-adult stages and the adult stage were also recorded.
7.2. Results Fish mortality No fish mortality was recorded throughout the entire test period.
Sea lice mortality: 14 days of bath treatment After 14 days of bath treatment with compound methoprene (AC), the fish had signifi-cantly less sea lice infestation than the corresponding control group (p<0.01 ) The effect of oral administration of JH analogue 59 on development and survival of sea lice-(Lepeophtheirus salmonis) on Atlantic salmon in sea water(Salmo salary Materials and methods Test compounds 10 The juvenile hormone analogue compound 59, 3-(3',7'-Dimethyloctyloxy)pyridine, was tested Test fish 15 400 Atlantic salmon of average weight 2.5 kg were distributed equally into two net pens (4x4x4 m) in a fish farm. The fish was deloused with NUVAN (dichlorvos) before the ex-periment. One group was used as a control and one group was treated with JH
analogue 59, 3-(3',7'-Dimethyloctyloxy)pyridine;, by oral administration. The fish farm was heavily infested with sea lice.
Preparation of feed containing JH analogue 59 Ordinary fish feed for Atlantic salmon (Felleskjopet) 12 mm was coated with JH
analogue 59, 3-(3',T-Dimethyloctyloxy)pyridine. The pure compound (liquid) was dissolved in Cape-line-oil to a concentration of 5.0% and then coated on feed pellet at a concentration of 10% oil. 9.4 kg feed coated with 59 was produced. The concentration was 5.0 g of sub-stance 59 per kg feed.
Oral administration of JH analogue.
Feed containing 59, 3-(3',T-Dimethyloctyloxy)pyridine, was fed on alternate days at a feeding rate of 0.5% per day. Ordinary feed was fed the days without medication and control fish was fed ordinary feed throughout the experiment. A total of 4 days of medica-tion was used and the total amount of 59, 3-(3',T-Dimethyloctyloxy)pyridine, applied was 20 gram per kg fish.
The fish was free of sea lice when the treatment started after the NUVAN
treatment Data recording In all net pens the number of sea lice was recorded 3 months after termination of the medication period (10 fish of each group). The distribution of the various stages of sea lice was recorded when the fish was removed from the net pens.
Results Fish mortality No fish mortality was recorded throughout the entire test period.
Table 8.1 Number of sea lice per fish 3 months after treatment 59, 3-(3',T-Dimethyloctyloxy)pyridine Control Fish no. Chalimus Pre-adultAdult ChalimusPre-adultAdult Average 12 18 32 23 23 52 Standard 6 23 15 11 9 23 deviation The number of sea lice at stages chalimus and adults are significantly lower in the group treated with JH analogue 59 than in the control group (a=0.05) The total average number of all sea lice stages in controls is 98 per fish while in the group treated with JH analogue 59 this number is reduced to 61. Because salmon in neighbour-ing cages were heavily infested with sea lice, migration of adult and pre-adult lice to the experimental groups occurred. The significant reduction in chalimus stages in the group treated with JH analogue 59 shows that development of copepodite through the four chalimus stages is inhibited by the treatment.
The effect of oral administration of JH analogues methoprene and hydroprene on devel-opment and survival of sea lice (Lepeophtheirus salmonis) on Atlantic salmon in sea wa-ter(Salmo salary Materials and methods Test compounds The juvenile hormone analogues methoprene (AC) and hydroprene (AD) were tested.
Test fish A number of 135 Atlantic salmon of average weight 117-145 grams was used in the ex-periment which took place in a fish disease facility. The test fish were distributed into tanks of 500 I with 45 fish per tank. Running sea water that was adjusted in respect of oxygen (at least 70% saturation in outlet water), salinity (34 promille) and temperature (11.5°C) was supplied to the tanks. The photoperiod was set at 18 hours of light and 6 hours of dark throughout the test period.
Preparation of feed containing the JH analogues methoprene (AC) and hydroprene (AD).
Ordinary fish feed for Atlantic salmon (Felleskjrapet) 3 mm was coated with the JH ana-logues methoprene (AC) and hydroprene (AD). The pure compounds were added to the feed in a mixer and then Capeline-oil was added to a concentration of 3.3%
while the mixer was running. 480 grams of medicated feed was made of each group. Two concen-trations of methoprene: 10 gram per kg feed (AC/X) and 2 gram per kg feed (AC/Y) were made. Also two concentrations of hydroprene (AD) were made: 10 gram per kg feed (AD/X) and 2 gram per kg feed (AD/Y) Cultivation of L. salmonis Adult female sea lice with mature ovaries were collected and the ovaries were separated from the female sea lice and incubated in running sea water (salinity 34 promille) at 10°C.
Newly hatched nauplius larvae were harvested daily and transferred to trays to produce infective copepodite larvae.
Challenge with sea lice During exposure to the sea lice, the water supply was stopped and the tanks were ad-justed to about 100 I of water. About 20,000 two days old copepodites were distributed to each tank. During exposure the tanks were aerated. After 2 hours the tanks were filled and the water supply was stopped. The fish were exposed to copepodites in stagnant water for 12 hours under aeration before the usual water regimen was re-established.
Oral administration of JH analogue Feed containing methoprene (AC/X and AC/Y) and hydroprene (AD/X and AD/Y) were fed at a feeding rate of 0.5% per day for 14 days. Control fish was fed ordinary feed through-out the experiment. A total of 371 gram of medicated feed was distributed to each medi-Gated fish group.
Data recording Five days following copepodite exposure, the success of infestation was recorded on 5 fish from each tank and the medication regimen was initiated. In all tanks the number of sea lice was recorded one day after termination of the medication period of 14 days (10 fish). The distribution of the various stages of sea lice was recorded. The recording of the various chalimus stages was simplified by recording chalimus stages 1 and 2 as juvenile chalimus (ChJ) whereas chalimus 3 and 4 were recorded as "old" chalimus (ChG).
The first and second pre-adult stages and the adult stage were also recorded.
Results Infection Due to a very high infestation rate of copepodites the number of sea lice attached to each fish was extremely high (> 100 per fish) and some mortality occurred among the fish.
The mortality of fish due to sea lice in the different groups is shown in Table 9.1:
Table 9.1 Tank Medication Mortality, number of fish out of 45 1 AC/X, 10 gram/kg, 14 6 days 2 AC/Y, 2 gram/kg, 14 5 days 3 Control fish 13 4 AD/X, 10 gram/kg, 14 1 days 5 AD/Y, 2 gram/kg, 14 5 days Highest mortality was observed in the control fish group which also had the largest num ber of sea lice (146 per fish). Lowest mortality was observed in the group medicated with hydroprene at highest concentration (AD/X) and which also had the lowest number of sea lice after medication (70 per fish).
Medication It was observed that the appetite was poor during feeding of medicated feed and that lots of medicated feed was not eaten. At sampling the day after medication only control fish 5 had feed pellets in the stomach. The reason for less intake of medicated feed could be due to taste problems. The actual dose of substance AC and AD presented for the fish is then considerably lower than the theoretical amounts. This is further supported by the fact that the average weight of medicated fish dropped during medication: AC/X from 142 to 123 gram, AC/Y from 145 to 117 gram, AD/X from 130 to 119 gram and AD/Y from 141 to 10 138 gram. The average weight of control fish increased slightly in the same period from 117 to 128 gram.
An ANOVA analysis of the number of sea lice per fish before medication and one day af-ter medication was performed, and the results are shown in the below Table 9.2.
Table 9.2 Tank Medication Number of Number of % change ANOVA signifi-sea sea in sea lice Ch.J lice pre-adultlice numbercance of be- reduc-fore medics-after medicationfrom beforetion to tion after medication 1 AC/X, 10 173 (n=5) 115 (n=10) 34 Yes, p =0.01 gram/kg, 14 days 2 AC/Y, 2 gram/kg,171 (n=5) 109 (n=10) 36 Yes, p=0.01 14 days 3 Control fish160 (n=5) 146 (n=5) 9 No 4 AD/X, 10 109 (n=5) 70 (n=10) 36 Yes, p <
gram/kg, 0.00001 14 days 5 AD/Y, 2 gram/kg,154 (n=5) 125 (n=10) 19 No 14 days The ANOVA analysis of the above data in Table 9.2 show that there are no significant re-duction of sea lice in the control fish group and in the AD/Y group, while the groups methoprene AC/X, AC/Y and hydroprene AD/X experienced a significant reduction of sea lice during medication.
A dose relation is seen with hydroprene in that the largest reduction in sea lice is ob-served with the highest concentration of hydroprene (AD/X).
The benefit of the administration of the JH analogues methoprene and hydroprene was clearly demonstrated by the lowering of the number of fish that died from sea lice infesta-tion and by the significant reduction in sea lice numbers.
Micro-emulsion concentrate for juvenile hormone analogues In the below Table 10.1 is given an example of a base micro-emulsion concentrate for bath treatment of fish with a juvenile hormone analogue.
The micro-emulsion is prepared in a tank kept at a constant temperature of 30°C, by adding the juvenile hormone analogue to the solvents (N-metyl-2-pyrrolidon and N-octyl-2-pyrrolidon) while stirring; and subsequently adding the remaining components (polyok-syl 35 castor oil, tetrapropylene benzenesulfonate Ca-salt and citric acid) to the mixture.
In bath treatment of fish, the juvenile hormone analogue is typically applied at concentra-tion of 0.1 to 1 ppm. I order to prepare a treatment bath of 100 m3 of water with a juvenile hormone analogue concentration of 0.1 ppm, 0.2 litre of micro-emulsion concentrate (stock solution) containing 50g juvenile hormone analogue per kg is added to the 100m3 of water. This micro-emulsion concentrate comprising the juvenile hormone analogue, can advantageously be diluted in a volume of water, e.g. 10 litres, before it is added to the aquatic environment wherein the fish to be treated is kept. A clear solution is seen when the micro-emulsion comprising the juvenile hormone analogue is added to the water.
Table 10.1 Micro-emulsion concentrate N-metyl-2-pyrrolidon 26.00 Kg N-octyl-2-pyrrolidon 25.00 Kg Polyoksyl 35 castor oil 41.00 Kg Tetrapropylene benzenesulfonate2.00 Kg Ca-salt Citric acid 1.00 Kg Juvenile hormone analogue 5.00 Kg Total 100.00 Kg
Claims (54)
1. Use of a compound having juvenile hormone activity, in the manufacturing of a medica-ment for controlling crustacean infestation of aquatic animals.
2. Use according to claim 1 wherein the aquatic animal is a fish.
3. Use according to claim 2 wherein the fish is selected from the group consisting of a species of the Salmonidae family, sea brass, sea bream, cod, halibut, wolf fish, flounder, aju and eel.
4. Use according to claim 3 wherein the fish is selected from the group consisting of Salmo salar, Salmo trutta, Salmo clarkii, Oncorhynchus gorbuscha, Oncorhynchus keta, Oncorhynchus nekra, Oncorhynchus kisutch, Oncorhynchus tshawytscha, Oncorhynchus mason, Oncorhynchus mossambicus, Oncorhynchus mykiss and Salvelinus species.
5. Use according to claim 1 wherein the crustacean is a species selected from the group consisting of species belonging to the Copepods class including a Lepeophtheirus spe-cies and a Caligus species and species belonging to the Isopoda class including Anilocra species.
6. Use according to claim 5 wherein the crustacean is selected from the group consisting of Lepeophtheirus salmonis, Caligus elongafus and Anilocra physodes L.
7. Use according to claim 1 wherein the crustacean is a species of the Branchiura class including an Argulus species.
8. Use according to claim 1 wherein the crustacean is of the Isopoda class.
9. Use according to claim 8 wherein the crustacean is of a species selected from the group consisting of a Anilocra species, a Chymothoa species, a Lironeca species, a Meinertia species, a Olencira species and a Bopyrus species.
10. Use according to claim 9 wherein the crustacean is selected from the group consisting of Anilocra physodes, Chymothoa exigua, Lironeca californica, Lironeca convexa, Liro-neca ovalis, Lironeca vulgaris, Meinertia oestroides, Meinertia parallels and Olencira praegustator.
11. Use according to claim 1 wherein the compound is selected from the group consisting of epofenonane, fenoxycarb, hydroprene, kinoprene, methoprene and triprene.
12. Use according to claim 1 where the medicament is a medicament which is to be ad-ministered to the aquatic animal via the oral or parenteral route or by adding the com-pound to the environment of the animal.
13. A juvenile hormone analogue compound selected from the group consisting of (i) a compound of the general formula I
where R1 is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted iso-prenoid or alkoxy substituted alkyl, R2 is hydrogen or alkyl, X is oxygen, sulfur, methylene, carbinol or carbonyl, Y is nitrogen or methinine and Z is nitrogen, methine or nitrogen ox-ide;
(ii) a compound of general formula II
where R1 is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, R2 is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
where R1 is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and R2 is methyl, ethyl or isopropyl, (iv) a compound of the general formula IV
where X is oxygen or sulfur and Ar is a heteroaromatic group, and (v) a compound selected from the group consisting of 55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperazine;
F-1: 3-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine; and F-5: 3-(4'-Phenoxybenzyloxy)pyridine, for use as a medicament for treating or preventing crustacean infestations in an aquatic animal.
where R1 is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted iso-prenoid or alkoxy substituted alkyl, R2 is hydrogen or alkyl, X is oxygen, sulfur, methylene, carbinol or carbonyl, Y is nitrogen or methinine and Z is nitrogen, methine or nitrogen ox-ide;
(ii) a compound of general formula II
where R1 is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, R2 is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
where R1 is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and R2 is methyl, ethyl or isopropyl, (iv) a compound of the general formula IV
where X is oxygen or sulfur and Ar is a heteroaromatic group, and (v) a compound selected from the group consisting of 55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperazine;
F-1: 3-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine; and F-5: 3-(4'-Phenoxybenzyloxy)pyridine, for use as a medicament for treating or preventing crustacean infestations in an aquatic animal.
14. A compound according to claim 13 of the general formula I where R1 is alkyl.
15. A compound according to claim 13 of the general formula I where R1 is branched al-kyl.
16. A compound according to claim 13 of the general formula I where R1 is alkoxy substi-tuted alkyl.
17. A compound according to claim 13 of the general formula I where R1 is cyclopropyl substituted isoprenoid including farsenyl.
18. A. compound according to claim 13 of the general formula I where R1 is gem-dihalocyclopropyl substituted isoprenoid.
19. A compound according to any of claims 13-18 of the general formula I where X is oxy-gen.
20. A compound according to any of claims 13-18 of the general formula I where X is sul-fur.
21. A compound according to any of claims 13-20 of the general formula I where Y is ni-trogen.
22. A compound according to any of claims 13-21 of the general formula where Z
is nitro-gen.
is nitro-gen.
23. A compound according to claim 13 of the general formula II having saturated side chains to the aromatic ring.
24. Use according to claim 1 wherein the compound having juvenile hormone activity is a juvenile hormone analogue compound according to any of claims 13-23.
25. Use according to claim 1 wherein the compound is selected from the group consisting compounds 1, 2, 4, 6, 7, 17, 34, 59, 60, 61, F-1, F-2, F-4 and F-5, as defined herein.
26. A method of controlling crustacean infestation of an aquatic animal, the method com-prising administering to said animal or to the aquatic environment of the animal an effec-tive amount of a compound having juvenile hormone activity.
27. A method according to claim 25 wherein the aquatic animal is a fish.
28. A method according to claim 27 wherein the fish is of a species belonging to the Sal-monidae family including Salmo salar, Salmo trutta, Oncorhynchus gorbuscha, Oncorhynchus keta, Oncorhynchus nekra, Oncorhynchus kisutch, Oncorhynchus tshawytscha, Oncorhynchus mason, Oncorhynchus mossambicus, Oncorhynchus mykiss, Salvelinus species and Salmo clarkii.
29. A method according to claim 26 wherein the crustacean is of the Copepoda class.
30. A method according to claim 29 wherein the crustacean is of a species selected from the group consisting of a Lepeophfheirus species and a Caligus species.
31. A method according to claim 30 wherein the crustacean is selected from the group consisting of Lepeophtheirus salmonis and Caligus elongatus.
32. A method according to claim 26 wherein the crustacean is of the Branchiura class.
33. A method according to claim 32 wherein the parasitic crustacean is an Argulus spe-cies.
34. A method according to claim 26 wherein the compound having juvenile hormone ac-tivity is selected from the group consisting of epofenonane, fenoxycarb, hydroprene, kino-prene, methoprene and triprene.
35. A method according to claim 26 wherein the compound having juvenile hormone ac-tivity is a juvenile hormone analogue compound selected from the group consisting of (i) a compound of the general formula I
where R1 is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted isoprenoid or alkoxy substituted alkyl, R2 is hydrogen or alkyl, X is oxygen, sulfur, methyl-ene, carbinol or carbonyl, Y is nitrogen or methinine and Z is nitrogen, methine or nitrogen oxide;
(ii) a compound of general formula II
where R1 is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, R2 is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
where R1 is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and R2 is methyl, ethyl or isopropyl, (iv) a compound of the general formula IV
where X is oxygen or sulfur and Ar is a heteroaromatic group, and (v) a compound selected from the group consisting of 55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperazine;
F-1: 3-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine; and F-5: 3-(4'-Phenoxybenzyloxy)pyridine.
where R1 is alkyl, branched alkyl including alkenyl or alkadienyl, optionally substituted isoprenoid or alkoxy substituted alkyl, R2 is hydrogen or alkyl, X is oxygen, sulfur, methyl-ene, carbinol or carbonyl, Y is nitrogen or methinine and Z is nitrogen, methine or nitrogen oxide;
(ii) a compound of general formula II
where R1 is 2,2-dimethylcyclopropyl, 2,2-dihalo-3,3-dimethylcyclopropyl, 2-methyl-1-propenyl or 3-methyl-1,2-butadienyl, R2 is hydrogen or methoxy, R3 is alkyl, alkenyl, ace-tyl, formyl or carbomethoxy, R4 is hydrogen or R3 and R4 together is methylenedioxy and X is oxygen or sulfur;
(iii) a compound of the general formula III
where R1 is 2-methylbutyl, 2,2-dimethylcyclopropyl or 2,2-dihalo-3,3-dimethylcyclopropyl and R2 is methyl, ethyl or isopropyl, (iv) a compound of the general formula IV
where X is oxygen or sulfur and Ar is a heteroaromatic group, and (v) a compound selected from the group consisting of 55: 4-Octylmorpholine;
56: 1-Octylpiperidine;
57: 2-(3',7'-Dimethyloctylsulfanyl)thiophene;
58: 1,4-Dioctylpiperazine;
F-1: 3-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine;
F-4: 2-[2'-(4"-Phenoxyphenoxy)ethoxy]pyridine; and F-5: 3-(4'-Phenoxybenzyloxy)pyridine.
36. A method according to claim 26 wherein the compound having juvenile hormone ac-tivity is a juvenile hormone analogue compound selected from the group consisting of compounds 1, 2, 4, 6, 7, 17, 34, 59, 60 and 61, as defined herein.
37. A method according to claim 26 wherein the compound having juvenile hormone ac-tivity is administered to the aquatic animal orally or parenterally.
38. A method according to claim 37 wherein the compound having juvenile hormone ac-tivity is administered via the feed for the aquatic animal.
39. A method according to claim 26 wherein the compound having juvenile hormone ac-tivity is administered to the aquatic animal by adding an antiparasitically active amount of the compound to the aquatic environment of said animal.
40. A method according to claim 39 wherein the compound is added to the aquatic envi-ronment in the form of a micro-emulsion.
41. A method according to claim 39 wherein the concentration of the compound having juvenile hormone activity in the environment of the aquatic animal is in the range of 1 ppb to 1 ppm.
42. A pharmaceutical composition for controlling crustacean infestation of an aquatic ani-mal, comprising a compound having juvenile hormone activity and at least one pharma-ceutically acceptable carrier.
43. A composition according to claim 42 which is in a form selected from the group con-sisting of a powder, a granulate, a suspension, an emulsion, a micro-emulsion and a solu-tion.
44. A composition according to claim 42 which is injectable.
45. A composition according to claim 42 further comprising a component selected from the group consisting of a wetting agent, an emulsifying agent, a bulking agent, a dispers-ing agent.
46. A composition according to claim 42 comprising a further anti-parasitically active com-pound.
47. A composition according to claim 46 where the further anti-parasitically active com-pound is selected from the group consisting of an organophosphate compound, a pyre-throid compound, hydrogen peroxide, formalin and a chitin synthesis inhibiting compound.
48. A composition according to claim 42 comprising as the compound having juvenile hormone activity a juvenile hormone analogue compound according to any of claims 13-23.
49. An aquatic animal feed composition comprising a compound having juvenile hormone activity.
50. A feed composition according to claim 49 comprising as the compound having juvenile hormone activity a compound according to any of claims 13-23.
51. A feed composition according to claim 49 which is in a form selected from the group consisting of a granulate, a pellet and an emulsion.
52. A feed composition according to claim 49 wherein the amount of the compound hav-ing juvenile hormone activity is in the range of 0.001 to 5 % by weight.
53. A feed composition according to claim 49 comprising a further anti-parasitically active compound.
54. A composition according to claim 53 where the further anti-parasitically active com-pound is selected from the group consisting of an organophosphate compound, a pyre-throid compound, hydrogen peroxide, formalin and a chitin synthesis inhibiting compound.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199901054 | 1999-07-23 | ||
DKPA199901054 | 1999-07-23 | ||
PCT/IB2000/001002 WO2001007047A2 (en) | 1999-07-23 | 2000-07-20 | Control of crustacean infestation of aquatic animals |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2378409A1 true CA2378409A1 (en) | 2001-02-01 |
Family
ID=8100468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002378409A Abandoned CA2378409A1 (en) | 1999-07-23 | 2000-07-20 | Control of crustacean infestation of aquatic animals |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1204413A2 (en) |
AU (1) | AU5837900A (en) |
CA (1) | CA2378409A1 (en) |
NO (1) | NO20020360L (en) |
WO (1) | WO2001007047A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001006853A2 (en) * | 1999-07-23 | 2001-02-01 | Bioparken As | Novel juvenile hormone analogues and their use as antifouling agents |
GB2371053A (en) * | 2001-01-13 | 2002-07-17 | David R Harper | Microbiological control of sea lice |
GB0605900D0 (en) * | 2006-03-23 | 2006-05-03 | Lipigen As | Modulators of nuclear receptors |
DK179642B1 (en) * | 2014-08-12 | 2019-03-06 | Institut de Recherche en Semiochimie et Ethologie Appliquee | Sea lice copepodits attachment inhibiting semiochemical |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3970758A (en) * | 1969-04-10 | 1976-07-20 | Stauffer Chemical Company | Certain geranyl phenyl ethers and their epoxides and their use in controlling insects |
CH568708A5 (en) * | 1969-04-30 | 1975-11-14 | Hoffmann La Roche | |
US4001339A (en) * | 1969-04-30 | 1977-01-04 | Hoffmann-La Roche Inc. | Phenyl derivatives |
CH526258A (en) * | 1970-03-25 | 1972-08-15 | Hoffmann La Roche | Pesticides |
US3709914A (en) * | 1970-07-30 | 1973-01-09 | Zoecon Corp | Methylenedioxyphenyl compounds |
US3832385A (en) * | 1970-08-03 | 1974-08-27 | Zoecon Corp | Substituted 4-alkylthiobenzoic acid esters |
US3868406A (en) * | 1970-08-03 | 1975-02-25 | Zoecon Corp | P-alkenyloxybenzoic acid esters useful for the control of insects |
DE2144936B2 (en) * | 1970-10-20 | 1974-02-21 | Ciba-Geigy Ag, Basel (Schweiz) | Terpene aryl ethers, processes for their preparation and pesticides containing them |
US3810989A (en) * | 1970-11-16 | 1974-05-14 | Stauffer Chemical Co | Control of confused flour beetles using geranyl phenyl ethers |
AU3666671A (en) * | 1970-12-22 | 1973-06-14 | Zoecon Corp | Compounds and syntheses |
CA1005821A (en) * | 1971-02-01 | 1977-02-22 | Clive A. Henrick | 2,4-diolefinic compounds and the control of insects |
CA919685A (en) * | 1971-03-15 | 1973-01-23 | The Dow Chemical Company | Ethers having juvenile hormone activity |
GB1339764A (en) * | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
GB1420533A (en) * | 1971-09-27 | 1976-01-07 | Cheminova As | Pyridine derivatives having juvenile hormone activity |
DE2210230A1 (en) * | 1972-03-03 | 1973-09-06 | Kolmar Laboratories | Antimicrobial and cytostatic thioethers - contg a polar residue |
JPS4892529A (en) * | 1972-03-11 | 1973-11-30 | ||
JPS49421A (en) * | 1972-04-21 | 1974-01-05 | ||
AU5620873A (en) * | 1972-06-16 | 1974-11-28 | F. Hoffmann-Laroche & Co. Aktiengesellschaft | Polyene derivatives |
DE2947648A1 (en) * | 1979-11-27 | 1981-08-06 | C.F. Spiess & Sohn GmbH & Co, 6719 Kleinkarlbach | USE OF TERTIARY HETEROCYCLIC AMINES AS A POTENCING AGENT FOR INSECTICIDES |
JPS59199673A (en) * | 1983-04-25 | 1984-11-12 | Sumitomo Chem Co Ltd | Nitrogen-containing heterocyclic compound, its preparation and pesticide containing the same |
JPS6036403A (en) * | 1983-08-08 | 1985-02-25 | Sumitomo Chem Co Ltd | Mixed insecticidal composition |
JPS6038303A (en) * | 1983-08-11 | 1985-02-27 | Sumitomo Chem Co Ltd | Extermination of flies |
JPS60215671A (en) * | 1984-04-10 | 1985-10-29 | Sumitomo Chem Co Ltd | Nitrogen-containing heterocyclic compound, its preparation, and noxious life controlling agent containing said compound as active component |
DE3522905A1 (en) * | 1985-06-27 | 1987-01-08 | Basf Ag | O-SUBSTITUTED 3-OXYPYRIDINIUM SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FUNGICIDES FOR PLANT PROTECTION |
JPS6287528A (en) * | 1985-10-15 | 1987-04-22 | Nitto Electric Ind Co Ltd | N-alkylmorpholine-containing composition for exodermis administration |
DE3614706A1 (en) * | 1986-04-30 | 1987-11-05 | Basf Ag | AGENTS FOR COMBATING MICROBES |
JP2522941B2 (en) * | 1987-04-28 | 1996-08-07 | 住友化学工業株式会社 | Ant control composition |
JP2707617B2 (en) * | 1987-08-11 | 1998-02-04 | 住友化学工業株式会社 | Preparation of honeybee larvae for fishing |
JPH01168602A (en) * | 1987-12-24 | 1989-07-04 | Nichibai Boeki Kk | Repellent against sanitary insect pest |
DE3825172A1 (en) * | 1988-07-23 | 1990-01-25 | Bayer Ag, 5090 Leverkusen | MEANS FOR CONTROLLING FLOWS |
GB9105694D0 (en) * | 1991-03-18 | 1991-05-01 | Hand Peter Animal Health | Control of sea lice in salmon |
AU660205B2 (en) * | 1991-12-23 | 1995-06-15 | Virbac, Inc | Systemic control of parasites |
DE4232561A1 (en) * | 1992-09-29 | 1994-03-31 | Bayer Ag | Fighting fish parasites |
IT1268625B1 (en) * | 1993-10-18 | 1997-03-06 | Sumitomo Chemical Co | COMPOSITION TO REGULATE INSECT GROWTH. |
IL112721A0 (en) * | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
GB9418328D0 (en) * | 1994-09-12 | 1994-11-02 | Grampian Pharm Ltd | Control of sea lice in seawater fish |
NO179816C (en) * | 1995-06-13 | 1996-12-27 | Nutreco Aquaculture Res Centre | Means for fighting parasites in farmed fish |
US5902808A (en) * | 1995-09-29 | 1999-05-11 | Buckman Laboratories International Inc. | Methods and compositions for controlling biofouling using N-alkyl heterocyclic compounds |
US6054454A (en) * | 1995-12-11 | 2000-04-25 | Novartis Corporation | Method of controlling fish parasites |
-
2000
- 2000-07-20 WO PCT/IB2000/001002 patent/WO2001007047A2/en not_active Application Discontinuation
- 2000-07-20 EP EP00944146A patent/EP1204413A2/en not_active Withdrawn
- 2000-07-20 CA CA002378409A patent/CA2378409A1/en not_active Abandoned
- 2000-07-20 AU AU58379/00A patent/AU5837900A/en not_active Abandoned
-
2002
- 2002-01-23 NO NO20020360A patent/NO20020360L/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU5837900A (en) | 2001-02-13 |
NO20020360L (en) | 2002-03-14 |
NO20020360D0 (en) | 2002-01-23 |
WO2001007047A3 (en) | 2001-12-20 |
WO2001007047A2 (en) | 2001-02-01 |
EP1204413A2 (en) | 2002-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1119256B1 (en) | Oral combination of lufenuron and nitenpyram against fleas | |
EP0255803A1 (en) | Process for the prevention of re-infestation of dogs and cats by fleas | |
WO2012001668A1 (en) | Anti-sea lice compositions and their use | |
JP2854097B2 (en) | How to control sea lice | |
NZ302661A (en) | Composition for controlling parasites comprising n phenyl-n'-benzoylurea derivatives | |
JP6267188B2 (en) | Treatment of fish populations with lufenuron | |
AU764007B2 (en) | Injectable preparation for controlling fish live comprising benzoyl urea derivatives | |
EP1306084B1 (en) | Compositions for the control of parasitic infestations in fish | |
JP4530307B2 (en) | Fish parasite therapeutic agent, method of use and use | |
KR100236586B1 (en) | 1-[n-(halo-3-pyridylmethyl)]-n-methylamino-2-nitroethylene derivatives for use against fleas on pets | |
JP3170077B2 (en) | Systemic control of parasites | |
US5416102A (en) | Method of preventing the reinfestation of dogs and cats by fleas | |
CA2378409A1 (en) | Control of crustacean infestation of aquatic animals | |
MXPA02005245A (en) | Combination of n phenyl n benzoyl urea derivative and nectin compounds for parasite control. | |
EP0917822B1 (en) | Method to control animal ecto-parasites | |
MX2012012196A (en) | Compositions and methods for control of sand flies and other blood sucking insects. | |
CN107920531B (en) | Agents for combating fish parasites | |
AU5118798A (en) | Method for the prevention of the reinfestation of warm-blooded animals by ectoparasites | |
MXPA97006416A (en) | Composition to control parasi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20050720 |